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ABSTRACT
Whilst progress has been made in reducing mortality in some cancers, mortality 
rates remain high in many cancers and there is a need to develop novel 
therapeutic strategies. In this thesis, various pharmacological strategies 
designed to enhance the activity of existing therapeutic drugs were evaluated. 
Cancer cells are dependent upon aerobic glycolysis (the Warburg effect) and 
glutamine uptake. Using clinically approved tyrosine kinase inhibitors and 
Bortezomib, significant enhancement of chemosensitivity was observed when 
used in combination with inhibitors of lactate dehydrogenase (Gossypol) and 
pyruvate kinase dehydrogenase (Dichloroacetate). In contrast, depletion of 
glutamine from media had to be extensive in order to induce cell death and cell 
death only occurred after prolonged exposure to glutamine-deprived conditions. 
This suggests that glutamine depletion strategies alone are unlikely to be 
successful but may be useful in combination with other agents targeting 
glutamine addiction in cancer cells. Finally, Temozolomide (TMZ) is an important 
drug in the treatment of glioblastomas but its activity is reduced by resistance 
mechanisms including O6 methyl guanine methyltransferase (MGMT) and 
mismatch repair (MMR). This thesis has identified analogues of TMZ (EA02-45, 
EA02-59, EA02-64 and EA02-65) that are MGMT and MMR independent in 
terms of inducing cell kill in vitro. These compounds are promising leads for 
future development. In conclusion, this thesis has demonstrated that interfering 
with the metabolic phenotype of cancer can enhance the activity of existing 
drugs and identified novel analogues of TMZ that circumvent drug resistance 
mechanisms that hamper the efficacy of TMZ.  
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Introduction 
The term cancer refers to a range of diseases characterised by unregulated cell 
growth, invasion of surrounding tissue and the ability for cancer cells to spread 
from the primary site to secondary sites within the body in a process known as 
metastasis. Cancer is primarily a genetic disease and during the transition of 
normal cells to malignant state, they acquire a number of characteristics or 
‘hallmarks’ (Hanahan and Weinberg, 2000; Hanahan and Weinberg, 2011). 
There are six essential alterations in cell biology that collectively dictate 
malignant growth and these are: (1) the ability to divide in the absence of growth 
factor stimulation, (2) the ability to divide in the presence of anti-growth signals, 
(3) the inability to undergo apoptosis, (4) the ability to maintain telomere length 
despite repeated cell divisions, (5) stimulation of angiogenesis, and (6) the ability 
to invade surrounding tissues and metastasize to other parts of the body (Figure 
1). 
        
Figure 1.1: The six hallmarks of cancer as described by Hanahan and Weinburg 
in their landmark publication in 2000 (Hanahan and Weinberg, 2000). 
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In the more recent version, the authors revisited these hallmarks using 
information from transgenic animals and biochemical assays that did not exist a 
decade ago. Hanahan and Weinberg also added two categories in the new 
updated paper: "enabling characteristics" and "emerging hallmarks.” The two 
enabling characteristics of cancer are tumour promoting inflammation and 
genetic instability and mutation, which assist cells in the transition from normal 
to oncogenic. The two emerging hallmarks; reprogramming of energy 
metabolism and evasion of the immune system have not been integrated into 
the canonical six because Hanahan and Weinberg remain unsure whether they 
are pervasive in all cancers (Hanahan and Weinberg, 2011). 
In addition to providing a solid basis for cancer research, the hallmarks have 
served to identify certain cell functions that have become therapeutic targets. 
However, the utility of such attempts has been limited because tumour cells have 
demonstrated an ability to develop resistance to drugs that disrupt a single 
pathway. This adaptability of cancer cells suggests to Hanahan and Weinberg 
that simultaneous targeting of two or more hallmark pathways may be a more 
effective approach to therapy. 
 
Cancer incidence and mortality 
Cancer is a common disease accounting for 8.2 million deaths in 2012 according 
to the World Health Organisation (WHO). It is estimated that there will be 14.2 
million new cases of cancer in 2012 worldwide with the incidence rates in males 
being greater than females by up to fourfold (Cancer, 2013). The most common 
cancers diagnosed were colorectal cancers, breast cancer, lung cancer and 
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prostate cancer and the most common causes of death from cancer were lung 
cancer, colorectal cancer, breast cancer and stomach cancer (Ferlay et al., 
2010). 
Regional and international differences in cancer incidence rates exist. In 
mainland Europe for example, the UK followed by France has the highest cancer 
incidence in males (426 per 100,000 and 385 per 100,000 respectively) and the 
UK followed by Demark has the highest incidence rate in females (347 per 
100,000 and 328 per 100,000 respectively). In the UK 324,579 people were 
diagnosed with cancer in 2010 and this equated to 521 cases in every 100,000 
people (males and females). In Europe the estimated number of cancer deaths 
in 2012 was 1.75 million (Ferlay et al., 2013), as compared with 1.256 million in 
2007. According to statistics and figures within Europe for men, lung cancer 
accounts for the most deaths (182,080 deaths). In women, breast cancer 
accounted for the highest number of deaths (87,843 deaths) (Malvezzi et al., 
2011). According to Cancer Research UK, cancer is responsible for more than 
one in four deaths in the UK and mortality rates are significantly higher in males 
than in females for all cancers combined. Therefore the need for prevention, 
early detection and new treatments is as obvious as it is imperative if the impact 
of cancer on the health and welfare of people and health service providers is to 
be reduced. 
 
Current treatments for cancer 
Following the diagnosis of a cancer patient, a team of practitioners are involved 
in the management and treatment of the disease. The main treatments used 
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today are surgery, radiation therapy and chemotherapy. Depending on 
pathological classification, staging and grading criteria, treatment regimes 
consist of either individual treatments or a combination of radiation therapy, 
chemotherapy and surgery or more. Surgery is the oldest form of cancer 
treatment and the most common of the treatments. There are different types of 
surgical procedures undertaken such as staging surgery, preventive surgery 
used to remove tissue that may become malignant, diagnostic surgery, and 
finally curative surgery. The latter is commonly used in the clinic to remove 
tumours confined to a single organ or site. In general, surgery is highly effective 
if the disease is localised and therefore early detection of tumours before they 
have metastasised is essential.  
Almost half of all cancer patients receive some form of radiation therapy during 
the course of their treatment regime. Radiation therapy uses high energy 
radiation to induce DNA damage and shrink the tumour. Radiation therapy is 
effective in treating cancers that cannot be excised surgically and considerable 
technical advances in the field have led to greater focusing of the radiation field 
to the tumour mass. In general terms however, the effectiveness of radiotherapy 
depends upon being able to direct the radiation to the tumour mass and it is not 
particularly effective against disseminated tumours. In these cases, a systemic 
based therapy that has the ability to ‘search and destroy’ cancer cells anywhere 
in the body is required.    
Chemotherapy is defined as the use of drugs to treat diseases such as cancer. 
Its origins in medicine stem back to the use of mustard gas in the First World 
War and the subsequent use of nitrogen mustard to induce remissions in 
patients with leukaemia (Ewig and Kohn, 1977). Today, the list of 
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chemotherapeutic drugs is extensive and can be broadly classified as classical 
cytotoxic and modern targeted therapeutics. The classical cytotoxic drugs target 
the process of cell replication via various mechanisms including DNA 
interactions (alkylation, intercalation, free radical damage induction etc.), DNA 
synthesis (the antimetabolites) and mitotic spindle poisons (Vinca alkaloids and 
Taxanes). Whilst these drugs can be extremely effective (Cisplatin based 
therapies are frequently curative against testicular cancer for example), their 
efficacy is constrained by toxicity towards normal tissues and the emergence of 
drug resistance (Hall and Tilby, 1992).  
 
Throughout the history of cancer chemotherapy and drug development, there 
was an acknowledgement that more selective anti-cancer drugs were needed 
but the search for the ‘magic bullet’ was limited by lack of knowledge of the 
fundamental biological processes underpinning the cancer process. Following 
the revolution in molecular biology that occurred in the 1980’s onwards, the 
biology of cancer is being unravelled and this has provided novel opportunities 
for drug discovery. In the 2011 version of the Hallmarks of Cancer review, 
Hanahan and Weinberg illustrate how this knowledge is leading to new 
therapeutic agents (Figure 1.2). 
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Figure 1.2: Understanding the biology of cancer is driving the development of 
new anti-cancer drugs. This figure taken from Hanahan and Weinberg (2011) 
illustrates some of the new, targeted therapeutic approaches being developed 
based on an understanding of the biology of cancer.  
 
These new therapeutics are designed to interfere with specific oncogenic drivers 
and are classified as targeted or biological anti-cancer drugs. This new 
generation of anti-cancer drugs have been effective in many cases (e.g. glivec 
and chronic myelogenous leukaemia) but toxicity to normal tissues and the 
emergence of new drug resistance mechanisms mean that the promised hope 
of significant and dramatic breakthroughs in the war on cancer have not 
occurred. Progress has been made and the continued drive towards developing 
drugs to target oncogenic drivers (mutated proto-oncogenes in particular) offers 
hope for new therapies and the possibility of individualising chemotherapy based 
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on genomic analysis of tumours before and during treatment (Wu et al., 2006). 
A detailed review of targeted therapeutics is beyond the scope of this thesis and 
readers are referred to excellent reviews on this topic for information   (Ciavarella 
et al., 2010; Lin; Wu et al., 2006). Suffice to say that whilst targeted therapies 
represent a significant advance in the way cancer is treated, their use is typically 
in combination with classical cytotoxic drugs and for the foreseeable future, 
cytotoxic drugs will still have an important role to play in the management of 
cancer. There remains a need to develop new anti-cancer drugs but equally, 
there is also a need to make better use of the drugs we already have. This thesis 
will address these issues in the form of two major chapters. The first looks at 
strategies designed to exploit the metabolic phenotype of cancers to enhance 
the activity of classical and targeted therapeutics and the second focuses 
predominantly on the drug Temozolomide and the evaluation of a series of novel 
analogues. The remainder of this introduction will focus on presenting the 
background to both these two topics. 
 
Metabolic reprogramming of cancer and the Warburg effect 
Louise Pasteur a leading scientist in his days described the phenomenon of 
“fermentation”, i.e. in order for cells to survive, cells switch from oxidative 
phosphorylation to glycolysis or fermentation in the absence of adequate 
oxygen. This phenotype was referred to as anaerobic glycolysis or the “Pasteur 
Effect” as described in figure 1.3A.  Almost seven decades later Otto Warburg 
in the 1920's described the same phenomenon in tumour cells demonstrating 
that the fermentation process also occurs but this time, it occurred in the 
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presence of adequate oxygen. Today this aberrant metabolic feature, found in 
rapidly proliferating tumour cells is known as the “Warburg Effect” figure 1.3B 
(Weinhouse, 1976).  
 
Figure 1.3: Schematic representation of the differences between oxidative 
phosphorylation, anaerobic glycolysis (A) and aerobic glycolysis (the Warburg 
effect, B). Normal cells in the presence of oxygen or in the absence of oxygen 
metabolize glucose to pyruvate. In the presence of oxygen, normal cells will 
convert pyruvate to ATP via the Krebs cycle and oxidative phosphorylation and 
during anaerobic glycolysis (absence of oxygen) pyruvate is converted to lactate 
(A). In contrast to normal cells, cancer cells are metabolically re-programmed to 
convert glucose to lactate even in the presence of oxygen (B) (Vander Heiden 
et al., 2009).  
 
Warburg observed that there was a correlation between the rates of glucose 
uptake, ATP production and the aggressiveness of tumour progression. 
Warburg originally assumed that aerobic glycolysis was a due to defects in 
mitochondrial respiration and he suggested that cancer might in fact be caused 
A B 
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by impaired mitochondrial metabolism (Gogvadze et al., 2008). It was later found 
that although there are defects in mitochondrial metabolism resulting in 
mitochondrial dysfunction (mutations in isocitrate dehydrogenase for example), 
the majority of tumours have essentially functional mitochondria but their activity 
is reprogrammed as a result of mutations in other pathways that drive the 
oncogenic process (Gatenby and Gillies, 2004a).  
Even in the presence of an adequate oxygen supply, many tumours metabolize 
the majority of the glucose they take up through glycolysis. This glycolytic 
phenotype is due to cancer specific defects that impinge upon various stages of 
glycolysis, the Krebs cycle and oxidative phosphorylation. A term referred to as 
‘cancers sweet tooth’ has been widely used to reflect cancers addiction to 
glucose and this has been exploited clinically to diagnose cancer and assess 
tumour response. The utilization of radiolabeled glucose analogue 18Fluoro-
deoxyglucose (18FDG) in positron emission tomography (PET) combined with 
computed tomography (CT), plays an indispensable role in modern diagnostic 
oncology. An example of how FDG and PET imaging can assist detection of 
tumours is presented in figure 1.4. The success of metabolic imaging and the 
clear benefits achieved with FDG PET in the assessment of patients with cancer 
has had a significant impact on the management of clinical disease (Cintolo et 
al., 2013). 
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Figure 1.4: Positron-emission tomography (PET) imaging with 
18fluorodeoxyglucose (18FdG) of a patient with lymphoma. The mediastinal 
nodes (purple arrow) and supraclavicular nodes (green arrows) show high 
uptake of 18FdG showing that tumours in these nodes have high levels of 18FdG 
uptake. The bladder (yellow arrow) also has high activity, because of excretion 
of the radionuclide (Gatenby and Gillies, 2004a). 
 
Today this feature of cancer biology has reached the forefront of research and 
it was classified as an emerging hallmark of cancer (Hanahan and Weinberg, 
2011). Key research questions have focused on understanding why cancer cells 
actively select this inefficient way of generating energy over oxidative 
phosphorylation and exploiting the opportunities it presents for therapeutic 
intervention. Selected issues of relevance to the work conducted in this thesis 
are reviewed in the following sections.   
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Mitochondria mediated apoptosis 
Evasion of cell death or apoptosis is a hallmark of cancers and a major cause 
of treatment failure. It is now well established that many anticancer agents 
induce apoptosis (Kaufmann and Earnshaw, 2000), and that disruption of 
apoptotic pathways can influence treatment response (Schmitt and Lowe, 1999). 
Since agents with distinct primary targets can induce apoptosis through similar 
mechanisms, mutations or suppression of apoptotic pathways results in drug 
resistance (Dive and Hickman, 1991). An established example of this is p53. 
When activated following drug treatment, a series of events are initiated leading 
to activation of apoptosis. Loss of p53 function can diminish drug induced cell 
death thereby promoting resistance and survival (Wallace-Brodeur and Lowe, 
1999).  
The apoptotic process has been well characterised and it progresses through a 
series of biochemical reactions. The programme of cell death is controlled by 
apoptotic signalling networks and there are two major pathways for initiating 
apoptosis: an extrinsic pathway that responds to external signals such as 
the Fas ligand (FasL) and tumour necrosis factor α (TNFα), and an intrinsic 
pathway where a process of Ca2+ induced apoptosis is activated following an 
alteration in the normal operation of the mitochondria. These two pathways 
activate the caspase cascade responsible for carrying out the orderly cell death 
programme. The Bcl-2 superfamily, which has both pro- and anti-apoptotic 
members, plays a major role in regulating apoptosis, with much of its activity 
focused on the intrinsic pathway where mitochondrial induced apoptosis is an 
important element (Antonsson, 2004). 
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 Apoptotic pathways 
The intrinsic signalling pathway for programmed cell death involves non-
receptor mediated intracellular signals, inducing activities in the mitochondria 
that initiate apoptosis. Stimuli for the intrinsic pathway include viral infections or 
damage to the cell by toxins, free radicals, or radiation. Damage to the cellular 
DNA can also induce the activation of the intrinsic pathway for programmed cell 
death. These stimuli induce changes in the inner mitochondrial membrane that 
result in the loss of transmembrane potential, causing the release of pro-
apoptotic proteins into the cytosol. Pro-apoptotic proteins such as cytochrome c  
activate caspases that mediate the destruction of the cell through many 
pathways. These enzymes also translocate into the cellular nucleus, inducing 
DNA fragmentation, a hallmark of apoptosis. The regulation of pro-apoptotic 
events in the mitochondria occurs through activity of members of the Bcl-2 family 
of proteins and the tumour suppressor protein p53.  
 
The extrinsic pathway begins when conditions in the extracellular environment 
determine that a cell must die. The pathway leading to apoptosis involves trans-
membrane death receptors that are members of the tumour necrosis factor 
(TNF) receptor gene superfamily. Members of this receptor family bind extrinsic 
ligands and transduce intracellular signals, one such example is of caspases 2 
and 8, these caspases recruit other signalling molecules such BID (BH3-
interacting domain death agonist) which activates tBID (truncated BID). tBID 
recruits and activates Bax which aids the release of cytochrome c and this 
ultimately result in the destruction of the cell or apoptosis (figure 1.5). The signal 
transduction of the extrinsic pathway involves several caspases that are 
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proteases with specific cellular targets. Once activated, the caspases affect 
several cellular functions as part of a process that results in the death of 
the cell(s). 
The ability to modulate the life or death of a cell is recognized for its immense 
therapeutic potential. Therefore, research continues to focus on the elucidation 
and analysis of the cell cycle machinery and signalling pathways that control cell 
cycle arrest and apoptosis. The permeabilization of the mitochondrial outer 
membrane is a potent way of unleashing apoptosis inducing activators. Multiple 
apoptosis inducing factors and biochemical cascades converge on the 
mitochondria to cause the deregulation and permeabilization of the outer wall 
eventually inducing apoptosis. The mitochondria exerts both vital and lethal 
functions in physiological and pathological scenarios. On the one hand, 
mitochondria are indispensable for energy production and hence the survival of 
cells and on the other hand maintains crucial regulators of the intrinsic pathway 
of apoptosis controlled by the p53 tumour suppressor shown in figure 1.5. 
The p53 tumour suppressor protein can elicit apoptosis by up regulating the 
expression of pro-apoptotic Bax protein in response to sensing DNA 
damage; Bax in turn stimulates mitochondria to release cytochrome c (Bonnet 
et al., 2007). Two gatekeeper caspases, 8 and 9, are activated by death 
receptors such as FAS or by the cytochrome c released from mitochondria. The 
caspases trigger the activation of a dozen or more effector caspases that 
execute the cell death, via selective destruction of sub cellular structures 
and organelles and the genome. As the mitochondrion is a key regulator of cell 
death and for this reason mitochondrial functions are often altered in neoplasia, 
therefore mitochondrial oriented drug therapy represent a promising approach. 
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Figure 1.5: The extrinsic death pathway is initiated by binding of the extracellular 
ligands, TNFα (tumour necrosis factor α) or FASL (apoptosis antigen-1 ligand), 
to death receptors TNFR1 and FAS. TNFR1 activation leads to the formation of 
a TRADD-RIP-TRAF2 complex, which signals through the NF-Kβ (nuclear factor 
Kβ 3). The TRADD-FADD-FLICEZ complex activates precaspases 8 triggering 
apoptosis through caspases 3 or the cleavage of BID. The intrinsic apoptotic 
pathway is initiated at the mitochondrion where cytochrome c interacts with 
APAF1 (apoptosis protease activating factor 1) to recruit and activate caspases 
9 forming apoptosomes which activate downstream caspases 3 and 7 (Benn 
and Woolf, 2004).  
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As stated previously, defects in the regulation of apoptosis are a hallmark of 
cancer and can contribute to the failure of chemotherapy. As both central 
metabolism and regulation of apoptosis converge on the mitochondria, one 
explanation for why cancer cells select for aerobic glycolysis is the avoidance of 
apoptosis via disturbance of mitochondrial physiology. To understand the link 
between metabolic reprogramming and apoptosis, some of the key features of 
the Warburg effect are described in the following paragraphs.  
Two enzymes that play a prominent role in the glycolytic phenotype of cancer 
are pyruvate dehydrogenase kinase (PDK) and lactate dehydrogenase A and B 
(LDHA and LDHB) both of which are regulated by the transcription factor, 
hypoxia inducible factor 1 (HIF-1) (Shaw, 2006). PDK is a gate-keeping enzyme 
that regulates the flux of pyruvate into the mitochondria via controlling the activity 
of the pyruvate dehydrogenase (PDH) complex. In the presence of activated 
PDK, PDH is inhibited via phosphorylation of PDH, limiting the entry of pyruvate 
into the mitochondria, where the Kreb cycle and oxidative phosphorylation take 
place. In conjunction with suppression of PDH activity, a key feature of the 
Warburg effect is the production of lactate by LDH. LDH catalyses the 
conversion of pyruvate to lactate and expression of LDH is elevated in many 
cancers (Fantin et al., 2006). The combined effect of elevated LDH and PDK 
activity therefore is to reduce the amount of pyruvate entering the Krebs cycle. 
Due to no carbon entering the Krebs cycle via glycolysis and suppression of 
oxidative phosphorylation, the membrane potential across mitochondrial 
membranes is disturbed (Frezza and Gottlieb, 2009). Pro-apoptotic mediators, 
like cytochrome c and apoptosis inducing factor, are protected inside the 
mitochondria. When the voltage potential is altered and redox sensitive 
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mitochondrial transition pore (MTP) opens, apoptotic factors are released in the 
cytoplasm and induce apoptosis (Halestrap, 2005). Mitochondrial depolarisation 
and increased reactive oxygen species (ROS) are associated with opening of 
the MTP and mitochondrial membrane potential and ROS production are 
dependent on the flux of electrons down the electron transport chain (ETC), 
which in turn are dependent on the production of electron donors (NADH, 
FADH2) from the Krebs' cycle. Suppressing the entry of pyruvate into the 
mitochondria by PDK and the inhibition  of acetyl-CoA production, will suppress 
both Krebs' cycle and the ETC and therefore inhibiting the opening MTP and 
therefore inhibiting apoptosis (Michelakis et al., 2008).  
 
Oncogenic regulation of the Warburg effect 
Tumour suppressors act to maintain tissue homeostasis, that is, to control the 
number of cells reproduced and behaviour of cells in a particular tissue within 
an organism (Fridman and Lowe, 2003). Tumour suppressors regulate one or 
more processes that prevent aberrant proliferation (Vogelstein et al., 2000). The 
most extensively studied tumour suppressor is p53, and it acts in response to 
diverse forms of cellular stress to mediate a variety of anti-proliferative and 
apoptotic effects. Hence, p53 can be activated by DNA damage, hypoxia, or 
aberrant oncogene expression to promote cell-cycle checkpoints, DNA repair, 
cellular senescence, and apoptosis. As a consequence, disruption of p53 
function promotes checkpoint defects, cellular immortalization, genomic 
instability, and inappropriate survival, allowing the continued proliferation and 
evolution of damaged cells. Given the profound proliferative advantage 
produced by loss of p53 function, it is not surprising that p53 is the most 
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commonly inactivated tumour suppressor gene in human cancer (Béroud and 
Soussi, 2003). In addition to its role in suppressing tumorigenesis, p53-
dependent apoptosis contributes to chemotherapy induced cell death (Fridman 
and Lowe, 2003). This was first demonstrated in studies using oncogenically 
transformed cells treated in vitro and in vivo, and was subsequently extended to 
a variety of settings. Consistent with the potential role for p53 in modulating 
chemotherapy in human cancers, loss of p53 function was linked to 
chemoresistance in certain tumour types (Johnstone et al., 2002; Wallace-
Brodeur and Lowe, 1999). These studies demonstrate the potential importance 
of apoptosis in cancer chemotherapy and initiated a link between cancer 
development and therapy. The intrinsic pathway centres on the mitochondria, 
which contain key apoptogenic factors such as cytochrome c. Major regulators 
of the intrinsic pathway are the pro- and anti-death members of the Bcl-2 family. 
These proteins reside at, or translocate to the mitochondria, controlling the 
release of the apoptotic inducing factors. 
 
Whilst p53 is known to play a key role in regulating apoptosis and cellular 
metabolism, the oncogenic regulation of the Warburg effect is much more 
complex involving multiple oncogenes and tumour suppressor genes (Kim and 
Dang, 2006), details of which are reviewed in detail elsewhere (Kim and Dang, 
2006; Koppenol et al., 2011). It is a widely held view that by switching their 
metabolism to aerobic glycolysis (which is driven by oncogenic events), cancer 
cells obtain a selection advantage by reducing their susceptibility to undergo 
apoptosis (Gogvadze et al., 2010). If this theory is correct, then interference with 
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the Warburg effect could have a major impact on ‘re-activating’ the apoptotic 
machinery making cells more susceptible to chemotherapy. 
 
Opportunities to reactivate apoptosis by inhibition of the Warburg effect 
1. Inhibition of LDH as a therapeutic strategy  
LDH is a tetrameric enzyme comprised of two major subunits A and B. Five 
isozymes of LDH exist that can catalyse the conversion of pyruvate and lactate 
and the proportion of A and B subunits determines the direction of the reaction. 
All A (LDH-A) catalyses the conversion of pyruvate to lactate and all B (LDH-B) 
catalyses the reverse reaction (lactate to pyruvate). LDH-A is typically over 
expressed in cancers and this leads to the production of high levels of lactate in 
cancers. High LDH-A levels have been linked to poor prognosis in many cancers 
(Billiard et al., 2013) and reduction of LDH A levels in cancer cells by siRNA or 
shRNA reduces cellular proliferative and tumorigenic potential both in vitro and 
in xenograft models (Fantin et al., 2006; Wang et al., 2012). 
The use of siRNA techniques to knock down LDH-A provides good evidence 
that LDH-A is a potential target for therapeutic intervention and several inhibitors 
of LDH-A have been explored (Granchi et al., 2011). One such inhibitor is 
Gossypol, a natural occurring compound originally isolated from cottonseed 
(Gossypium). It has been successfully used as a contraceptive drug for males 
in China where it was first discovered. The drug interferes with 
spermatogenesis, exerting a specific and reversible effect on developing sperm 
at concetrations of 2.5 -12.5µM (Wu, 1989). Gossypol has been shown to 
chelate zinc, bind arginine and lysine, and inactivate enzymes essential for 
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oxidative phosphorylation. Gossypol has been shown to inactivate LDH amongst 
other enzymes (Tuszynski and Cossu, 1984). Since gossypol exhibited such a 
broad spectrum of reactivity against metabolic enzymes such as LDH, it was 
investigated as a potential therapeutic compound against tumour cells that rely 
heavily on anaerobic metabolic pathways for production of energy. It was initially 
discovered by Tuszynski and Cossu (Tuszynski and Cossu, 1984) to have 
anticancer effects against several tumour cell lines grown in tissue culture, and 
in the most sensitive cell lines to gossypol, cell death or apoptosis was induced 
(Zhang et al., 2003). Gossypol competes with NADH for binding to lactate 
dehydrogenase which leads to competitive inhibition of lactate dehydrogenase 
activity (Yu et al., 2001). Gossypol has also demonstrated selective cytotoxic 
activity against cancer cells as opposed to normal cells or noncancerous cells 
(de Peyster and Wang, 1993; Volate et al., 2010) and these findings have been 
verified by independent research groups from different laboratories (de Peyster 
and Wang, 1993). Gossypol has been shown to inhibit the growth of various 
cancer cell lines in vitro, including breast, colon, prostate, and leukaemia. 
Inhibition of cytoplasmic and mitochondrial enzymes (including key enzymes for 
DNA replication and repair), uncoupling of oxidative phosphorylation, and 
depletion of cellular ATP are proposed mechanisms of action. In experimental 
models therefore, gossypol induces cytotoxic effects and is known to inhibit cell 
proliferation and prevent metastases in many different types of cancers (Stein 
et al., 1992; Volate et al., 2010). 
The clinical testing of Gossypol began in the early 1970s in China, and to date 
the drug has been studied extensively in thousands of men (Wu, 1989). Clinical 
data from Gossypol in men have found Gossypol to be orally active and relatively 
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safe and effective but follow-up studies indicate that inhibition of 
spermatogenesis may continue following discontinuation in up to 50% of men 
after 2 years. Concerns regarding the lack of predictable, reversible effects have 
delayed the further clinical development of gossypol in Western countries 
(Coutinho, 2002).  Nevertheless, phase I and II clinical trials are being conducted 
using gossypol in non-Hodgkin lymphomas, breast and prostate cancer. These 
results show limited promise in the clinic but its ultimate value as a clinical 
treatment requires further studies. Gossypol is nevertheless a good 
experimental tool to study the effects of pharmacologically inhibiting LDH in the 
preclinical setting.  
 
2. Inhibition of PDK1 as a therapeutic strategy   
PDK1, which is one of four family members, was identified as a direct HIF-1 
target gene in hypoxic cells (Michelakis et al., 2008). PDK1 phosphorylates and 
inactivates the mitochondrial PDH complex. Suppression of PDH by PDK1 
inhibits the conversion of pyruvate to acetyl-CoA, thereby attenuating 
mitochondrial function (apoptosis) and respiration (Kim et al., 2006). Because 
non-hypoxic stabilization of HIF through oncogenic events has been observed 
in many types of tumours (Semenza, 2003), PDK1 levels are also up-regulated 
in most tumours irrespective of oxygen tension. Elevation of PDK1 therefore 
prevents pyruvate from being metabolised by PDH resulting in increased lactate 
production which is a key feature of the Warburg effect (Kim and Dang, 2006).  
 
Kim et al. (Kim et al., 2006) demonstrated that PDK1 mediated inhibition of the 
TCA cycle would result in increased glycolysis and ATP levels by shunting 
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pyruvate toward lactate production. By suppressing PDK1 expression by RNA 
interference, the growth of P493-6 (B cells) cells in hypoxia were impaired as 
compared to cells treated with control siRNA. The results suggested that PDK1 
is necessary for the proliferation of P493-6 cells under hypoxic conditions and 
demonstrated that it is a potential target for therapeutic intervention.  
Wun Lu et al. (Lu et al., 2008) found that PDK1 and PDK3 were up regulated 
under hypoxic conditions, and were interested to determine the roles of PDK1 
and PDK3 on HIF1α-induced drug resistance. Transient transfection of HeLa 
cell with siRNA against and ablation of PDK1 resulted in increased cell death 
under hypoxia. Furthermore double knockdown of both PDK1 and PDK3 caused 
more cell death under hypoxia suggesting an additive effect on cell survival. 
When these cells were treated with cisplatin or paclitaxel, PDK1 deficient cells 
exerted cell death compared with PDK3 knockdown cells. Simultaneously, 
knockdown of PDK1 and PDK3 resulted in further increasing susceptibility to 
drug killing. Together, this research provides compelling evidence to 
demonstrate that PDK1 and PDK3 played an additive effect in HIF1α-induced 
drug resistance (Kim et al., 2006; Wang et al., 2004). 
 
A small molecule of 150 Daltons called dichloroacetate (DCA) is a known 
inhibitor of PDK1, and is often used to treat lactic acidosis in patients with 
mitochondrial defects (Stacpoole et al., 1994). DCA inhibits PDK1 resulting in 
the reduction of lactic acid production by reducing glycolysis and increasing 
oxidative phosphorylation (Ko and Allalunis-Turner, 2009). Inhibition of PDK1 by 
DCA caused a shift in metabolism resulting in the reactivation of oxidative 
phosphorylation and altered mitochondrial membrane potential. The 
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depolarization of the mitochondrial membrane potential resulted in the release 
of the apoptotic effector cytochrome c and increased apoptosis (Michelakis et 
al., 2008). An increase in reactive oxygen species generated by oxidative 
phosphorylation up-regulates the voltage gated K+ channel, leading to 
potassium ion efflux and caspase activation inducing apoptosis. The reversal of 
metabolic reprogramming of cancer cells by DCA has been shown to also 
reverse cell resistance to apoptosis mediated by the mitochondria. DCA returns 
the membrane potential of cancer cells towards the levels of the healthy cells, 
without affecting the mitochondria of healthy cells as illustrated in figure 1.6. This 
suggests that forcing cancer cells to respire aerobically can reinstate 
mitochondrial oxidative phosphorylation and counteract the reduction of 
apoptosis caused by the Warburg effect.  
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Figure 1.6: In cancer cells mitochondrial glucose oxidation is suppressed and 
cytoplasmic glycolysis is favoured. The Kv channels (blue) are blocked and 
cannot allow the exit of K+ out of the cell (panel A) and an increase entry of 
Ca++ contributes to the inhibition of apoptosis and a hyperpolarised state within 
the mitochondria. PDH activation by DCA or LDH inhibition promotes oxidative 
phosphorylation by increasing the entry of pyruvate into the mitochondria and 
Krebs cycle. Consequently, apoptosis increases cell proliferation and tumour 
growth decreases (Michelakis et al., 2008). K+: Potassium ions, MTP: 
Mitochondrial transition pore, AOS: Activated oxygen species, Kv: Potassium 
voltage  
 
In vitro, DCA inhibition of PDK was observed at low concentration of 10–
250μM in a dose dependent manner (Stacpoole, 1989). DCA administered at 
35–50 mg kg−1 lead to a decrease in lactate levels (> 60%)  (Parolin et al., 2000). 
 25 
 
DCA inhibits its own metabolism and the half-life increases with subsequent 
doses (Stacpoole et al., 2006). However, there is a plateau of this effect and 
DCA serum levels do not continue to rise with chronic use (Mori et al., 2004). 
DCA has been used for the past 40 years in children and adults with diverse 
disease states including healthy volunteers.  
In 2006 the first randomised control trial were carried out with DCA in congenital 
mitochondrial diseases. The first, a blinded placebo-controlled study was 
performed with oral DCA administered at 25 mg kg−1 day−1 in 30 patients 
(Kaufmann et al., 2006) with MELAS syndrome (mitochondrial myopathy, 
encephalopathy, lactic acidosis and stroke-like episodes). Following this a 
second study was undertaken another randomised placebo controlled double 
blinded study with 21 children suffering from congenital lactic acidosis treated 
with DCA orally at 25 mg kg−1 day−1 for 6 months demonstrated mild peripheral 
neuropathy (Stacpoole et al., 2006). No other toxicities were reported. 
Peripheral neuropathy is a frequent complication induced by taxane, platinum 
and vinca-alkaloid chemotherapies, it also can be induced by DCA but may 
depend on whether cancer patients have prior or concurrent neurotoxic therapy 
(Michelakis et al., 2008). 
 
3. Combination of inhibitors of the Warburg effect with anti-cancer drugs  
Whilst the evaluation of inhibitors of cancer cell metabolism as single agents is 
ongoing, it is important to state that most chemotherapeutics will be used in 
combination with other cytotoxic or targeted therapeutics. In the context of 
targeting cancer metabolism and the potential for re-activating the apoptotic 
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phenotype of cancers by altering mitochondrial physiology, combination therapy 
is particularly relevant. Several studies have demonstrated that modulating LDH 
and/or PDK can increase the efficacy of cytotoxic drugs (Papandreou et al., 
2011), little is known about the effects metabolic inhibitors would have on 
targeted therapeutics. Before discussing this in more detail, some background 
to targeted therapeutics is provided in the following paragraphs.  
 
As illustrated in figure 1.2 (Hanahan and Weinberg linking hallmarks to drugs) 
modern anti-cancer drugs are designed to target key features of tumour biology. 
One example of this early success of directed targeting is tamoxifen, which 
targets the estrogen receptor, a key driver of a significant number of breast 
cancers. Such success gave rise to new agents which targets proteins specific 
to cancer (Levitzki, 2013). Aberrant cell signalling is a hallmark of cancer and 
considerable efforts have been made to interfere with this process. Tyrosine 
kinase inhibitors (TKIs) represent one class of drugs that have been developed 
and many are approved for clinical use (Paul and Mukhopadhyay, 2004). Thus, 
targeted therapies represent a new addition to the arsenal of agents used to 
treat cancer and this approach has already lead to beneficial clinical effects. A 
detailed review on targeted therapeutics is beyond the scope of this thesis and 
readers are referred to excellent reviews on the topic for further details 
(Ciavarella et al., 2010; Sawyers, 2004).  
Combination therapy involves using two or more chemotherapy drugs against 
cancer cells to achieve a better or improved therapeutic outcome. Combination 
chemotherapy was first established in the 1960s when scientists wondered 
whether the approach to treating tuberculosis using a combination of antibiotics 
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to reduce the risk of resistance would work for the treatment of cancer (Mayer 
and Janoff, 2007). Chemotherapeutic agents are often combined to enhance 
efficacy by reducing recurrence and delaying the emergence of resistant 
tumours. Combination therapy is now an integral part of cancer chemotherapy 
treatments and the benefits provided have demonstrated great therapeutic 
efficacy. An example of the potential benefits from combination studies are 
presented in the treatment of breast cancer in the paper published by Miles and 
his research team who found that combination and sequential therapy both have 
their place in the treatment of metastatic breast cancer (Miles et al., 2002). 
Newer drug combinations, such as paclitaxel/trastuzumab or 
capecitabine/docetaxel, show survival advantages over single-agent therapy 
and have manageable safety profiles and potentially reduce the risk of toxicity, 
which may improve quality of life (Bull et al., 1978; Norton, 1997).  
Following DCA treatment, it has been described and shown that DCA can 
potentiate the activity of a number of conventional cytotoxic drugs such as 
Temozolomide (Michelakis et al., 2010), Doxorubicin (Heshe et al., 2011) and 
platinum based drugs (Olszewski et al., 2010). Little is known however about 
the ability of DCA to potentiate the activity of targeted therapeutics such as TKIs. 
Because of the link between oncogenic pathways and the Warburg effect, it is 
conceivable that inhibition of the Warburg effect could impact upon the activity 
of TKIs. Similarly, it is possible that the reverse situation could also apply in that 
TKI’s could potentiate the activity of inhibitors of aerobic glycolysis. As no studies 
have investigated combinations of TKI inhibitors and inhibitors of glycolysis, this 
thesis will address this issue. The first aim of the thesis therefore is to determine 
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whether or not manipulation of the Warburg effect using inhibitors of PDK1 and 
LDH can enhance the activity of clinically used TKIs.  
 
Glutamine ‘addiction’ and the promotion of cell proliferation. 
In addition to the avoidance of apoptosis, it is now believed that switching 
metabolism to aerobic glycolysis supports the proliferation of cancer cells which 
is a key hallmark of cancer biology (Buchheit et al., 2012). In order to maintain 
cell proliferation, cells require the building blocks needed to replicate (i.e. lipids, 
nucleic acids etc.). This need requires the cell to make anabolic metabolites. In 
normal tissues that are rapidly proliferating, the glycolytic pathway and Krebs 
cycle are diverted from energy production (catabolism) to biosynthetic pathways 
(anabolism). Full details of the metabolic reprogramming that promotes cell 
proliferation has been extensively reviewed elsewhere (Hanahan and Weinberg, 
2011; Le et al., 2012) but the remainder of this section will focus on the glutamine 
dependency of tumours and how this promotes cell proliferation.  
 
Historically, during research in to the nutritional requirements of cell lines 
growing in vitro, Eagle observed that the glutamine consumption rate of many of 
the cell lines exceeded the consumption of any other amino acid by tenfold 
(Harry, 1955). Cell lines he studied could not proliferate in the absence of 
exogenous glutamine and many could not maintain their viability in the absence 
of glutamine (Kaadige et al., 2009). Glutamine has therefore been recognized 
for a long time to play a unique role in the metabolism of proliferating cells. Most 
tumours consume and utilize glutamine at much higher rates than other amino 
acids (Daye and Wellen, 2012). Although glutamine is a non-essential amino 
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acid in normal and non-dividing tissue, it is essential for the proliferation of most 
cells and the viability of some cancer cells that have become addicted to 
glutamine. Glutamine metabolism contributes to the ability of cancer cells to 
continuously grow and proliferate by supporting ATP production and 
biosynthesis of proteins, lipids, and nucleic acids (DeBerardinis and Cheng, 
2010; Wise and Thompson, 2010). Recent investigations into glutamine 
metabolism have greatly expanded our understanding of the role and regulation 
of glutamine metabolism in cancer (DeBerardinis and Cheng, 2010; Reinert et 
al., 2006). Glutamine plays several important metabolic roles in the cell, it serves 
as a carbon source for energy production, contributes carbon and nitrogen to 
biosynthetic reactions and co-operates with glucose uptake to drive the Warburg 
effect, all of which are summarised in figure 1.7.  
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Figure 1.7: Glutamine metabolism in cancer cells and the glutaminolytic 
pathway. Steps in the Krebs cycle are in blue. The malate aspartate shuttle 
appears in orange and the green color represents enzymes overexpressed in 
tumors. The numbers denote the following enzymes: 1 = glutaminase, 2 = 
Glutamine oxaloacetate transaminase (glutamate dehydrogenase can also 
convert glutamate to α-keto-glutarate), 3 = α-keto-glutarate dehydrogenase, 4 = 
succinate dehydrogenase, 5 = fumarase, 6 = malate dehydrogenase, 7a = 
cytosolic malic enzyme, 7b = mitochondrial malic enzyme, 8 = citrate synthase, 
9 = aconitase, 10 = lactate dehydrogenase (Wise and Thompson, 2010). 
 
The synthesis of fatty acids is essential for cell replication and one route involves 
the removal of citrate from the TCA cycle where it is converted to acetyl CoA in 
the cytosol and utilised to drive fatty acid and phospholipid synthesis (Le et al., 
2012). Because the TCA cycle is now interrupted, alternative sources of α-keto-
glutarate are required to maintain the supply of oxaloacetate required to drive 
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the next ’cycle’ of the TCA (Figure 1.6). Cancer cells achieve this objective by 
importing glutamine and converting this to α-keto-glutarate that enters the TCA. 
This truncated form of the TCA is a key feature of tumour cell metabolism and it 
has provided novel opportunities for therapeutic intervention, details of which 
are reviewed in detail elsewhere (Frezza and Gottlieb, 2009). These include the 
development of inhibitors of key enzymes involved in glutamine metabolism and 
several are in preclinical development.  
 
An alternative approach is to employ a glutamine depletion strategy on the basis 
that reduction or removal of external sources of glutamine would slow down 
tumour growth. Various glutaminases have been identified and are being 
explored but one avenue of research involves the potential use of L-
asparaginase. An essential nutrient in rapidly growing cancer cells is 
asparagine, which is required to proceed through the G1 cycle of cell division. 
Asparagine is important in protein, DNA, and RNA synthesis. The amino acid, 
L-asparagine, is a nutritional requirement of both normal and cancer cells. Unlike 
normal cells, however, certain leukemic cells cannot synthesize asparagine and 
must consequently rely on an external supply in the plasma and tissues. The 
administration of the enzyme, L-asparaginase, destroys this free source of 
asparagine, starving and killing certain cancer cells (Pieters et al., 2011). In 
conjunction with being able to remove asparagine, it is reported that L-
asparaginase also has glutaminase activity (Cairns et al., 2011). There are 
several commercial sources of L-asparaginases, each of which is isolated from 
different bacteria. The version from Erwinia chrysanthemi (Erwinase or 
Kidrolase) is believed to have significantly enhanced glutaminase activity 
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compared to L-asparaginase isolated from Eschericia coli (Narta et al., 2007). 
Whilst these therapeutics are not approved for use in solid tumours, the fact that 
they can deplete glutamine warrants further investigation as a possible adjunct 
to conventional targeted or classical chemotherapeutic agents.   
Cells with enhanced expression of Myc oncoproteins are particularly sensitive 
to glutamine deprivation, which induces depletion of TCA cycle intermediates, 
resulting in a depression of ATP levels and a delay in growth, and apoptosis. 
Myc drives glutamine uptake and catabolism by activating the expression of 
genes involved in glutamine metabolism, including GLS (glutaminase) 
and SLC1A5 (glutamine transported) (Gao et al., 2009). Silencing glutaminase 
mimicked some of the effects of glutamine deprivation, including growth 
suppression in Myc-expressing cells and tumours (Cheng et al., 2011). 
Understanding glutamines role in metabolic pathways, and how cancer cells 
benefit from glutamine addiction can be informative, and used in clinical 
oncology as a potential therapeutic strategy.  Glutamine is a highly versatile 
nutrient whose metabolism has implications for tumour biology and may provide 
novel therapeutics opportunities. Key questions remain concerning the level of 
glutamine depletion that cells have to be exposed to in order to reduce cell 
growth and what happens to cells when glutamine levels return to normal after 
a period of depletion. These and other issues represent the second major 
objective of this thesis and they will be addressed in chapter two.   
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Development of novel analogues of Temozolomide 
As stated previously, the search for new and more effective therapies to treat 
cancer remains a major objective in the War on Cancer. New chemotherapies 
can be developed along target orientated principles or by developing analogues 
of successful drugs that have been engineered to provide solutions to problems 
encountered by the parent drug. Temozolomide (TMZ) is one such example and 
the third chapter of this thesis will present studies designed to evaluate novel 
analogues of TMZ. Initially however, the pharmacological properties of TMZ are 
reviewed below.  
 
Temozolomide; mechanisms of action and resistance 
TMZ is an orally available, mono functional alkylating pro-drug that has 
demonstrated efficacy in the treatment of a variety of solid tumours, including 
primary malignant brain tumours and metastatic melanoma (O'Reilly et al., 
1993). TMZ has certain advantages over many existing alkylating agents 
because of its small molecular weight; this allows TMZ to efficiently cross the 
blood brain barrier (Agarwala and Kirkwood, 2000). Thus, TMZ is effective 
against primary brain tumours; TMZ can be administered orally providing it with 
a unique bioavailable profile and is also associated with a low incidence of 
severe adverse toxicity. 
TMZ achieves its cytotoxic effect mainly by methylating the O6 position of 
guanine. This leads to damaged DNA and to apoptosis (O'Reilly et al., 1993). 
TMZ spontaneously hydrolyses to methyltriazen-1-yl imidazole- 4-carboxamide 
(MTIC) as shown in figure 1.8. MTIC then degrades into methyldiazonium ion, 
which is the active methylating species. TMZ can methylate the DNA at N7 
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guanine, O3 adenine, and O6 guanine but TMZ is most effective when it 
methylates DNA at O6 position of guanine (Beier et al., 2008). This adduct can 
be removed by the DNA repair protein O6-methylguanine-DNA- 
methyltransferase (MGMT) therefore TMZ displays its highest efficacy against 
tumours lacking MGMT expression due to a methylated MGMT promoter (Hegi 
et al., 2005).  
 
 
Figure 1.8: A schematic diagram for the conversion of Temozolomide to MTIC. 
It undergoes rapid chemical conversion in the systemic circulation at 
physiological pH to the active compound MTIC (Friedman et al., 2000).  
 
TMZ has few side effects but like most chemotherapy drugs it does induce 
toxicity due to its unselective nature. Common side effects of TMZ include, 
constipation, fatigue, and headache, loss of appetite, low blood platelet count, 
nausea, vomiting, and weakness. Some of the less common side effects include 
anaemia, low white blood cell count, hair loss, rash, and convulsions, swelling 
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in the arms or legs, difficulty sleeping, and/or a tingling or burning feeling. Some 
of the more major side effects are myelosuppression, a condition in which bone 
marrow activity is decreased, resulting in fewer red blood cells, white blood cells, 
and platelets (Friedman et al., 2000).  
There are several mechanisms of resistance to alkylating agents, these include 
defects in DNA mismatch repair (MMR), increased excision repair, and 
increased enzymatic removal of alkyl groups (Zhang et al., 2012). One of the 
key enzymes responsible for removing methyl groups from O6-methylguanine is 
O6-alkylguanine transferase (AGT), also known as MGMT. Over expression of 
MGMT can lead to resistance to the cytotoxic effects of TMZ (Agarwala and 
Kirkwood, 2004; Lee et al., 1994). However, TMZ is able to deplete the levels of 
MGMT in various cell types, thus reducing the potential for drug resistance 
(Newlands et al., 1992). TMZ induced cell death is inhibited by cells expressing 
MGMT. Therefore cells which express MGMT are immune from the effect of 
TMZ. Conversely, cells that lack MGMT expression are sensitive to TMZ. 
 
Mutagenic lesions which are not repaired by MGMT are recognized by the post-
replication MMR. MMR corrects DNA mismatches generated during DNA 
replication, thereby preventing mutations from being passed on in dividing cells. 
The MMR system is required for cell cycle arrest and/or programmed cell death 
(apoptosis) in response to certain types of DNA damage such as TMZ and other 
alkylating agents (Li, 2007). MMR is not functional in many tumours, either as a 
result of a mutation in one of the MMR genes, or because of an epigenetic 
silencing due to methylation in the hMLH1 gene (Aarnio et al., 1999; 
Hoeijmakers, 2001). Defective MMR pathway and increased expression of 
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MGMT can lead to the tumour resistance to TMZ. This deficiency in the MMR 
pathway results in a failure to recognize and repair the O6-MG adducts produced 
by TMZ (Friedman et al., 2000). DNA replication continues past the O6-MG 
adducts without cell cycle arrest or apoptosis providing immunity to cancer cells 
from TMZ. MGMT can be successfully inactivated by free guanine base 
derivatives, with alkyl groups at the O6 position, which act as 
‘‘pseudosubstrates.’’ O6-benzylguanine and O6-(4-bromothenyl)guanine 
(PaTrin-2) have been identified as the most promising MGMT in-activators (Liu 
and Gerson, 2006). Compared to Temozolomide used as a single agent, the 
combination PaTrin2/Temozolomide has been shown to significantly increase 
tumour growth inhibition in human melanoma xenografts. PaTrin2 and O6-
benzylguanine have recently entered phase II clinical trials. A key question for 
future research is the development of analogues of TMZ that circumvent these 
resistance mechanisms. A series of novel analogues of TMZ were synthesised 
by Dr Richard Wheelhouse (School of Pharmacy, University of Bradford) and 
the initial evaluation of these compounds against a panel of cell lines that have 
been characterised for MMR and MGMT is presented in chapter 3 of this thesis.  
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Aims and objectives 
Whilst considerable progress has been made in reducing mortality in some 
forms of cancer, mortality rates for other cancers remain high and there is a 
need to develop novel therapeutic approaches. Understanding the biology of the 
disease and the pharmacology of drugs used to treat cancer is driving forward 
the development of novel anti-cancer drugs and novel strategies to make 
existing drugs work better. Within this context, the purpose of this thesis is to 
address three key issues; 
 The first is whether or not the Warburg effect can be pharmacologically 
manipulated to enhance the activity of targeted anti-cancer drugs. Specifically, 
inhibitors of LDH-A and PDK1 will be evaluated in a panel of cell lines and 
combination studies in vitro will be conducted using a series of clinically 
approved tyrosine kinase inhibitors.    
The second objective is to determine what effect glutamine depletion strategies 
have on the viability and response of cells in vitro. These studies will address 
key issue’s relating to the ‘depth’ of glutamine depletion required to induce 
cellular responses and whether or not the effects of glutamine depletion are 
reversible once glutamine levels return to normal.  
Finally, TMZ is a multi-billion dollar drug used to treat glioblastoma. Whilst effect, 
its efficacy is compromised by drug resistance mechanisms including 
deficiencies in MMR and over-expression of MGMT. Novel analogues of TMZ 
will be evaluated with the aim of identifying second generation compounds that 
retain the desirable properties of TMZ but have improved properties in terms of 
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circumvention of the drug resistance mechanisms that have reduced the efficacy 
of TMZ. 
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CHAPTER TWO 
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Introduction 
Targeting the glycolytic phenotype and glutamine addiction in cancer 
cells.  
The Warburg effect is now considered to be an emerging hallmark of cancer 
(Hanahan and Weinberg, 2000) and is defined by the increased dependence of 
cancer cells on glucose metabolism even in the presence of oxygen. As normal 
cells transform into cancerous cells, the normal processes for energy production 
of glycolysis, the Krebs cycle and oxidative phosphorylation are reprogrammed 
and cells become reliant on glucose metabolism and aerobic glycolysis 
(Gatenby and Gillies, 2004b). Aerobic glycolysis rapidly generates ATP and 
diverts carbon from glucose into precursors for the synthesis of nucleotides, 
proteins, and lipids to support the growth of the rapidly dividing population of 
cancer cells. As a consequence of this switch, glucose is preferentially 
catabolized to lactate, rather than fully metabolized via mitochondrial oxidative 
phosphorylation. 
As indicated in chapter 1 and summarised in figure 2.1, there are two major 
molecules that are catabolized in substantial quantities in cancer cells. These 
are glucose and glutamine. Glucose and glutamine supply the majority of the 
carbon, nitrogen, free energy and reducing equivalents necessary to support cell 
growth and division in proliferating cells. Inhibiting LDH activity impairs cell 
proliferation (Dang et al., 2009). Furthermore, highly proliferative cells need to 
produce excess lipid, nucleotide, and amino acids for the creation of new 
biomass. Therefore excess glucose is then diverted through the pentose 
phosphate pathway (PPP) to create nucleotides (Kim and Dang, 2006). 
 41 
 
Glutamine supplies nitrogen for nucleotide and hexosamine synthesis while 
glutamate is the nitrogen donor for the synthesis of many nonessential amino 
acids. It is now widely appreciated that many of the signalling pathways that 
promote oncogenesis also reprogram glutamine metabolism, and in many cells 
the dependence on glutamine is absolute, a condition termed glutamine 
addiction (Wise and Thompson, 2010).  
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Figure 2.1: The role of glucose and glutamine in cancer cells as a result of 
metabolic adaptations imposed by oncogenes and tumour suppressors. As a 
consequence of such metabolic reprogramming is that glucose can be utilised 
for the production of ATP via glycolysis resulting in lactate production and 
glutamine utilized for the synthesis of amino acids, lipids and nucleotides, which 
are essential for proliferating cells. Such metabolic adaptations are central to 
tumour progression in turn providing the opportunity for therapeutic targets such 
as glutamine, LDH and PDK (Wise and Thompson, 2010). 
 
Oncogenic events in cancer drive the switch from oxidative phosphorylation to 
aerobic glycolysis and lactate production by inducing the expression and 
activation of several glycolytic enzymes. To begin with the aberrant PI3K/AKT 
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signalling induces the expression and cell surface expression of glucose 
transporters (GLUT1 and GLUT4) (Gottlob et al., 2001). Followed by the 
transcriptional oncoproteins MYC and HIF-1α induce the expression of several 
glycolytic enzymes including LDH A. In addition, MYC enhances glutamine 
catabolism by inducing the transcription of the glutamine transporters (ASCT2; 
also known as SLC1a5) and by suppressing miR-23a/b, which normally blocks 
glutaminase translation (Gao et al., 2009). Studies have detected an up-
regulation of high affinity glutamine transporters in cancer (Fuchs and Bode, 
2005). One primary example, SLC1A5 (ASCT2), is a direct target of the Myc 
oncoprotein, and is up-regulated in a host of cancers. In the search for Myc-
regulated mitochondrial proteins, Gao et al. found that glutaminase protein 
levels were significantly up-regulated in Myc-overexpressing cells. Myc-induced 
metabolic reprogramming triggered cellular dependency on exogenous 
glutamine as a source of carbon for the maintenance of the mitochondrial 
membrane potential and macromolecular synthesis prolonging survival (Gao et 
al., 2009). Higher glutaminase expression results in increased glutamine uptake 
and catabolism. MYC also promotes the production of the M2 form of pyruvate 
kinase (PKM2), a normally embryonic isoform of pyruvate kinase that is 
catalytically inefficient and favours aerobic glycolysis (Christofk et al., 2008). 
Finally, coupling of glycolysis to oxidative phosphorylation is disabled by MYC 
or HIF-1α directed induction of pyruvate dehydrogenase (PDH) via pyruvate 
dehydrogenase kinase 1 (PDK1), which phosphorylates and inactivates PDH 
(Kim et al., 2006).  
Glutamine has an important role in cell growth and energy metabolism. 
Glutaminolysis, consists of two steps: the first is catalysed by glutaminase and 
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converts glutamine to glutamate, whereas the second is catalyzed by glutamate 
dehydrogenase (GDH) and converts glutamate to α-ketoglutarate (α-KG). There 
are two types of glutaminase in mammalian cells, kidney-type glutaminase 
(GLS1) and liver-type glutaminase (GLS2) (DeBerardinis et al., 2008). Metabolic 
flux experiments show that cancer cells exhibiting Warburg like metabolism do 
not stop utilizing the TCA cycle instead these cells come to rely on glutamine as 
the carbon source for the TCA cycle (DeBerardinis et al., 2007). Many cancer 
cells rely on glutamate anaplerosis to refill the TCA cycle. Glutamate enters the 
TCA cycle via its conversion to α-ketoglutarate by the actions of either 
transaminases or glutamate dehydrogenase (DeBerardinis and Cheng, 2010). 
Malate and citrate created by the TCA cycle are then available for further 
biosynthetic pathways. This allows the intermediates generated by the TCA 
cycle to feed other biosynthetic pathways as precursors. Therefore, cancer cells 
are dependent on glutamine to maintain the TCA cycle (Kamata et al., 2007). 
This indicates that elevated glutaminolysis is linked to drug resistance. 
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Rationale and Aims 
As described in chapter 1 and elaborated above, the switch to aerobic glycolysis may 
be beneficial to tumour cells as it contributes towards the avoidance of apoptosis, a 
classical hallmark of cancer. By reactivating oxidative phosphorylation, it is possible in 
some cases to reactivate the apoptotic phenotype making cells more susceptible to 
therapeutic drugs. Inhibiting LDH and/or PDK1 by Gossypol or DCA respectively 
may lead to an increase of pyruvate in the mitochondria promoting glucose 
oxidation, reactivating apoptosis and decreasing proliferation and tumour 
growth. Inhibitors of key enzymes involved in the Warburg effect (e.g. DCA) have 
been shown to potentiate the activity of certain drugs (e.g. Temozolomide 
(Michelakis et al., 2010), Doxorubicin (Heshe et al., 2011) and platinum based 
drugs (Olszewski et al., 2010).  
However, no studies have investigated whether DCA can influence the activity 
of TK inhibitors. In addition to targeting the glycolytic phenotype, glutamine 
depletion strategies may also be effective in reducing the cancer burden. A 
variety of human cancer cell lines have shown sensitivity to glutamine starvation, 
including pancreatic cancer, glioblastoma multiforme, acute myelogenous 
leukemia, and small cell lung cancer (Wise and Thompson, 2010). It is not 
known however whether glutamine depletion has to be complete to cause cell 
death or what effect replenishment of the media with glutamine has on cell 
survival. The specific aims of the work conducted in this chapter are listed below: 
 
1. To determine the activity of inhibitors of LDH A (Gossypol) and PDK1 
(DCA) against a panel of cell lines in vitro. 
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2. To determine whether the activity of TKIs are influenced by inhibition of 
PDK1 and LDHA 
 
3. To determine how much glutamine needs to be depleted in order to 
reduce the growth or kill tumour cells in vitro.  
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Methods and Materials 
Materials 
All chemicals were purchased from Sigma Aldrich (Poole, United Kingdom) 
unless stated otherwise. All tissue culture consumables were purchased from 
Costar (Amsterdam, Netherlands).  
 
Cell Lines and Maintenance 
Isogenic human colon colorectal carcinoma cell lines HCT116 p53+/+ (wild type) 
and HCT116 p53-/- (null type) cell lines were obtained from the Vogelstein 
laboratory (Johns Hopkins Kimmel Cancer Centre, Baltimore, USA) and were 
cultured in Roswell Park Memorial Institute 1640 (RPMI 1640) culture medium, 
supplemented with 10% foetal bovine serum, sodium pyruvate (1mM) and L- 
Glutamine (2mM). To study the effects of different media on cell growth, HCT116 
p53+/+ and HCT116 p53-/- cells were also maintained in Dulbecco’s Modified 
Eagle Medium (DMEM) Glutamax II (purchased from GIBCO, UK) 
supplemented with 10% foetal bovine serum and sodium pyruvate (1mM). 
These cells were maintained at 37˚C in a 5% CO2 humidified atmosphere in an 
incubator until required for experimental use. 
 
Routine maintenance and Sub-culturing of cell lines  
Cells were kept in exponential growth by regular sub-culturing and were not 
allowed to reach more than approximately 70% confluence (estimated by visual 
inspection of flasks). First the medium from the flask was removed and the 
adherent cells growing at the bottom of the flask were washed twice using Hanks 
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Balanced Salt Solution (HBSS) followed by the addition of trypsin (1-3ml of 
0.25% trypsin EDTA) to the cell layer. Following incubation for up to 3 minutes 
at room temperature or at 37oC until the cells had detached, 10ml of complete 
RPMI 1640 culture medium or DMEM culture medium was then added to the 
cells to stop the enzymatic activity of trypsin. The cell suspension was 
subsequently centrifuged for 5 minutes at 800g. After obtaining a cell pellet, the 
supernatant was discarded and re-suspended in 20ml of complete RPMI 1640 
or DMEM culture medium. Complete RPMI 1640 or DMEM medium was added 
to new T75 flasks and 1ml of cell suspension was added in to the T75 flasks. 
Flasks were then incubated in 5% CO2 and at 37˚C. 
 
Cell counting using a haemocytometer 
After cleaning the haemocytometer with 70% ethanol, the glass cover slip was 
fixed in to place over the etched grids and pressed down until Newton’s rings 
were visible. A small volume of cell suspension was pipetted on to the 
haemocytometer (approximately 10µl) at the point where the cover slip and the 
haemocytometer met. The fix between the cover slip and the haemocytometer 
aided uptake via capillary action of the cell suspension. As illustrated below in 
figure 2.2 cells were counted in 5 squares (labelled in red). Cells on the left and 
the top edges of the grid were counted (in green) whereas cells that covered the 
right side of the chamber and bottom edges of the grid were not counted (in red). 
Using the cell count from five individual counts the mean was calculated. The 
mean cell number is multiplied by x104 to give the number of cells/ml. Cells were 
counted using an inverted microscope at X10 objective magnification. 
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Figure 2.2: A schematic diagram of a haemocytometer and the five chambers 
(in red) used to count cells. Top left (A) represents the five chambers used for 
counting cells and the bottom right (B) represents the process used to count 
cells that fall on the edge of the haemocytometer grids. Cells which have been 
marked with a green tick are cells included in the count and cells which are 
marked with a red cross are excluded from the count. 
 
Chemosensitivity studies: Experimental conditions for drug exposure  
The response of cells to cytotoxic drugs was determined using the MTT assay 
(van Meerloo et al., 2011). Details of the cytotoxic agents used are presented in 
subsequent sections below but the generic protocol is described here. Briefly, a 
2x104 cells/ml cell suspension was made in a final volume of 10ml. Cells were 
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plated into a 96 well plate at a density of 2x103 cells per well as illustrated in 
figure 2.3. Following overnight incubation (at 37˚C) the culture medium was 
removed from the wells and replaced by medium containing varying 
concentrations of drug (8 wells per drug concentration). Column 1 rows A-H 
were used for the blank (RPMI 1640 or DMEM only) and column 2 rows A-H 
were used for the control (cells plus RPMI 1640 or DMEM medium). The 
remaining columns (3 to 12) contained compounds at a range of concentrations. 
The 96 well plates were incubated for further 6 days (144 hours at 37˚C in a 5% 
CO2) before carrying out the MTT assay. All experiments were done in triplicate. 
For experiments that involved a 1 hour drug incubation, 96 well plates were 
prepared as described above and following the 1 hour exposure, cells were 
washed twice with HBSS (200 µl per well). After washing the wells, fresh 
medium (200µl) was added to all the wells and cells were incubated (at 37˚C) 
for a further four days before carrying out the MTT assay. All experiments were 
done in triplicate. 
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Figure 2.3: A schematic diagram of a 96 well plate describing the setup of the 
plate for chemosensitivity testing. After seeding the plate with cells it was 
incubated overnight to allow the cells to adhere to the bottom of the wells before 
the drug was added. The triangle (in red) represents the drug concentration 
gradient; column 3 contained the highest concentration of drug whereas column 
12 contained the lowest drug concentration. Columns 1 and 2 represents the 
blank (no cells, media only) and the control (containing cells and the drug vehicle 
only) respectively.  
 
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) is a yellow, 
water soluble tetrazolium salt that is reduced by viable cells to purple, water 
Each well contains 2,000 cells per well 
(Rows A – H and column 2 -12). 
BLANK 
Rows A – H and column 1 
contain media only  
R
O
W
 
Concentration of drug 
CONTROL 
Rows A – H and column 
1 contain media and 
cells only 
 52 
 
insoluble formazan crystals. The reduction takes place in the mitochondria of 
viable cells by enzymes such as succinate dehydrogenase (van Meerloo et al., 
2011). To each well of the 96 well plate(s), 20µl of 5mg/ml MTT solution is added 
and the plate(s) are incubated at 37oC for 4 hours. After the incubation, the 
content of the wells was removed leaving behind the formazan crystals at the 
base of the well. The formazan crystals were solubilized by the addition of 150µl 
of dimethyl sulfoxide (DMSO). Once the crystals dissolved, the absorbance of 
the solution was determined at 540nm using a Multiskan Ex-microplate reader 
(Thermo Scientific, UK) with a 540nm filter. The mean absorbance of the blank 
was subtracted from all other mean values in order to obtain the true 
absorbance. Percentage cell survival was determined according to the following 
equation:  
 
 
Dose response curves were generated by plotting % cell survival against drug 
concentration and the IC50 was determined. IC50 is defined as the concentration 
of drug required to reduce cell survival by 50%.   
 
 
Measuring the Response of Cells to Dichloroacetate, Gossypol, 
Bortezomib and Tyrosine Kinase Inhibitors 
The response of HCT116 p53+/+ and HCT116 p53-/- following continuous 
exposure to gossypol was determined using the MTT assay as described above. 
Gossypol was dissolved in complete RPMI 1640 culture medium at a stock 
concentration of 100mM, aliquoted and stored at -20oC until required for 
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experiments. HCT116 p53+/+ and HCT116 p53-/- cells were exposed to a range 
of drug concentrations (100mM to 0.195mM in two fold dilutions) for 6 days 
before cell survival was determined using the MTT assay.  
 
The response of HCT116 p53+/+ and HCT116 p53-/- following continuous 
exposure to DCA was determined using the MTT assay as described above. 
DCA was dissolved in complete RPMI 1640 culture medium and was made up 
fresh on the day of the experiment. Initially, HCT116 p53+/+ and HCT116 p53-/- 
cells were exposed to DCA (concentrations ranged from 100mM to 0.195mM 
using a 2 fold dilution) for 6 days. Subsequent studies used increased 
concentrations of DCA (ranging from 0.976mM to 500mM using a 2 fold dilution) 
to ensure a full dose response curve was obtained. DCA was made up with 
complete RPMI 1640 and DMEM for the respective experiments. The response 
of HCT116 p53+/+ and HCT116 p53-/- maintained in complete RPMI 1640 and 
DMEM was determined to see whether differences in the culture medium 
influenced chemosensitivity. 
 
The response of HCT116 p53+/+ and HCT116 p53-/- cells following continuous 
exposure to TKIs and Bortezomib was determined using the MTT assay as 
described above. HCT116 p53+/+ and HCT116 p53-/- cells were exposed to TKIs 
and Bortezomib for 6 days. TKI concentrations ranged from 0.156µM to 80µM  
using a 2-fold dilution and Bortezomib ranged from 0.302nM to 156nM and the 
concentration of DCA ranged from 0.976mM to 500mM. All dilution were made 
using a 2-fold dilution. All compounds were dissolved in DMSO at the stock 
concentrations indicated in table 1. Working concentrations of TKIs and 
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Bortezomib were all made up with complete RPMI 1640 to ensure that the final 
DMSO concentration was < 0.1% in all cases.  
 
Name Molecular 
weight 
Stock 
concentration 
Solvent  
Dasatinib 488.01 100mM DMSO 
Imatinib 589.71 100mM DMSO 
Gefitinib 446.9 100mM DMSO 
Masitinib 498.65 100mM DMSO 
Bortezomib 384.24 100mM DMSO 
Sorafenib 464.82 100mM DMSO 
Vandetanib 475.35 100mM DMSO 
Nilotinib 529.52 75mM DMSO 
Sunitinib 398.47 50mM DMSO 
 
Table 1: Table of each individual drugs used in experiments to measure the 
cytotoxicity against HCT cell lines and the basic information regarding each 
drug. All compounds were obtained from LC Laboratories (Woburn, USA). 
 
Combination chemosensitivity studies: DCA in combination with TKIs and 
Bortezomib 
Based on the studies above, the IC50 for the individual TKIs and Bortezomib 
were used for the combination study. The diluent was made up of complete 
RPMI 1640 culture medium plus the TKI or Bortezomib at their respective IC50 
values. The diluent was used to make up the highest concentration of DCA 
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(500mM) and subsequent dilutions to provide a range of DCA concentrations. 
Cells were exposed to drug combinations for 6 days prior to analysis of cell 
survival using the MTT assay. 
For the combination study there were variations to the layout of the plate. This 
was the inclusion of an additional control. The first of the two controls was 
column 2 rows A-H (cells plus medium) the second was column 3 rows A-H 
(cells plus medium with TKI/Bortezomib only). The second control was used to 
calculate % cell survival when evaluating the effectiveness of the combination 
experiments. 
 
Statistical analysis 
Statistical analysis was carried out on data for Bortezomib and TKI alone and in 
the presence of DCA. Student –T test was used to find out whether the data has 
differences or similarities in respect to the experimental groups. A value of less 
than 0.05 (P value <0.05) was considered statistically significant.  
 
Western Blot Analysis for PDK1 inhibition by DCA 
The purpose of the experiments was to detect PDH, PDK1 and the 
phosphorylated form of PDH (p-PDH) in the absence and presence of DCA. In 
the absence of DCA the following should be detected PDH, PDK1 and p-PDH 
whereas in the presence of DCA, PDK1 should be inhibited therefore the 
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detection of PDH should be detected whereas the detection of the p-PDH should 
be reduced. 
Preparing cells for Western Blot analysis 
HCT116 p53+/+ and HCT116 p53-/- cells were seeded in T25 flasks at 1x105 in 
8ml of complete RPMI 1640 culture medium. A total of 6 T25 flasks were 
prepared for each cell line, flask one was used for the control, the remaining five 
flasks were labelled 1-5 and were incubated for five days at 37oC and 5% CO2. 
The concentration of DCA ranged from 31.25mM to 500mM (5 concentrations 
made with a 2 fold dilution factor) and cells were exposed to DCA for 1hour.  
Following drug incubation, the supernatant in each flask was collected and 
placed in to labelled universal tubes (this was done to ensure none of the 
detached cells in suspension were lost). Adherent cells growing at the bottom of 
the flask were washed with HBSS twice followed by trypsinisation; 1ml of trypsin 
(0.25% trypsin EDTA) was added to the cell layer and incubated for up to 3 
minutes at room temperature until the cells had detached. Phosphate buffer 
saline (PBS) solution was added (5ml) to the cells to dilute and reduce the 
enzymatic activity of trypsin. The cell suspension was centrifuged (800g for 5 
min), following the centrifugation the supernatant was discarded keeping the cell 
pellet, which was washed with cold PBS (5ml) twice.  
Proteins were extracted from the cell pellet by adding lysis buffer (0.5mM EDTA, 
0.5mM EGTA, 5mM NaCl, 1mM Tris-HCl (pH 7.5), 1mM dithiothreitol, protease 
inhibitor mixture (protease inhibitor cocktail 2 and 3, Sigma Aldrich, Poole, 
United Kingdom) and 10% Triton X-100 in deionised H2O (3 times the volume of 
the pellet) followed by sonication (2 x 10 second bursts using settings of 5 cycles 
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and 50% power (US-70 from Phillip Harris Scientific (Lichfield, UK)). The lysates 
were centrifuged for 10 minute at 10,000g and 4°C, the supernatant was 
collected for Western blot analysis and the protein concentration was calculated 
by using the Bradford assay. 
 
Measurement of protein concentration using the Bradford Assay  
The total protein concentration in each sample was measured using the 
Bradford assay (Bradford, 1976), which relies on the linear relationship between 
absorption and the amount of Coomassie dye bound to the proteins present in 
the lysate. The standard curve was established by preparing serial dilutions of 
bovine serum albumin (BSA) ranging from 0.0312mg/ml to 1mg/ml (BSA stock 
solution 1mg/ml).  The blank (distilled water) and protein standards (50µl) were 
added to 1,450ml of Bradford reagent, mixed and incubated for 10 minutes at 
room temperature. The absorbance at 595nm was measured using a MultiScan 
Spectrum spectrophotometer (Thermo Scientific, UK). All calibration and 
unknown samples were assayed in triplicate. The concentration of protein in test 
samples was determined from the linear part of the standard curve (using the 
equation derived from linear regression analysis). Samples where absorbance 
values fell outside the linear range of the calibration curve were diluted to ensure 
absorbance values fell within the linear range.  Typically, the cell lysate samples 
were diluted by a factor of 20 in order to obtain absorbance values within the 
linear range. The dilution factor was used to determine the final protein 
concentration in samples.   
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Western Blot Analysis  
Western blots were performed by running 50µl of protein extracts suspended in 
extraction buffer on a 12% SDS polyacrylamide gel and transferred to 
nitrocellulose membranes by standard procedures described below. The 
apparatus used for all electrophoresis experiments was the Biorad mini trans-
well blot system and the first step in the Western blotting process was to prepare 
the gel; to make a 12% resolving gel the following reagents were added: 
Resolving gel (12%) 
Components 5ml = 1 gel 10ml = 2 gels  Storage 
deionised H2O 1600µl 3300µl Room temperature 
30% acrylamide 2000µl 4000µl Fridge 4oC 
1.5M Tris (pH8.8) 1300µl 2500µl Room temperature 
10% SDS 50µl 100µl Room temperature 
10% APS 50µl 100µl Freezer -20 oC 
TEMED 2µl 4µl Room temperature 
*APS= Ammonium persulfate, *SDS= sodium dodecyl sulfate, *TEMED= 
Tetramethylethylenediamine 
 
Once the resolving gel was been poured a thin layer of iso-butanol was added 
on top of the newly poured gel. After the gel has polymerised, the iso-butanol 
was removed and any excess iso-butanol was removed via washing with dH2O 
and blotting paper. The stacking gel (see below) was poured on top of the 
running gel and the combs were carefully inserted avoiding air bubbles. The 
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combs provide wells for the sample and were left in for up to 15 minutes to all 
the stacking gel to polymerise. 
Stacking gel 
Components 1ml = 1 gel 2ml = 2 gels Storage 
deionised H2O 680µl 1400µl Room temperature 
30% acrylamide mix 170µl 330µl Fridge 4oC 
1.0M Tris (pH6.8) 130µl 250µl Room temperature 
10% SDS 10µl 20µl Room temperature 
10% APS 10µl 20µl Freezer -20 oC 
TEMED 1µl 2µl Room temperature 
 
Once polymerised, the gels were placed into the tank and immersed in 
electrophoresis buffer (25mM Tris base, 192mM glycine, 0.1% SDS and pH 8.3).  
The combs were removed from the gel and the wells were washed with 
electrophoresis buffer to remove any un-polymerised acrylamide.   
 
The ladder (5ul of the ladder to 15ul of sample buffer (2x)) was prepared, 
followed by the blank (10ul of sample buffer plus 10ul of PBS) and the samples 
(x amount of cell sample to equal parts of sample buffer (2x) and the remaining 
volume added was deionised water (final volume 20ul)). These were all 
incubated for 15 minutes at 90oC. The ladder (protein molecular weight 
standards used as molecular weight markers) was added to the first well 
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followed by the samples to subsequent wells and the gels were run at 60 volts 
for 15-20 minutes, allowing the samples to run through the stacking gel at the 
same rate passing through in to the running gel. Once the samples reached the 
running gel the voltage was increased to 120volts until the ladder reached the 
bottom. The final step was to remove the gels and prepare them for the transfer 
process. 
Before removing gels for transfer process, 500ml of the transfer buffer was 
prepared (48mM Tris base, 39mM glycine, 0.04% SDS, 20% methanol) and 
placed in a large container. A small volume of transfer buffer was removed and 
placed in small container which was used to soak the blotting paper (x2) and 
white pads (x2). 
Nitrocellulose paper was cut to the size of the gel(s) and soaked in to deionised 
water for one minute. During this time the gels were removed from the glass 
plates housing the gels and prepared for the transfer process. The transfer 
cassettes were opened (black side down) and placed in the large container 
containing transfer buffer, the white pads were placed on to the cassette (black 
side) followed by blotting paper. The gel was placed on top of the blotting paper 
then the nitrocellulose paper was placed over the gel. Finally placing the second 
piece of blotting paper over the nitrocellulose paper followed by the white pad 
carefully removing any air bubbles. The transfer cassette was closed by bringing 
the clear side down and locking both sides in to place. The cassette was then 
placed in to the cassette holder (the black side facing the panel which was 
black). The cassette(s) holders were placed in to the tank, which was then filled 
with transfer buffer followed by placing the lid over the top and sealing the tank. 
The transfer process was ready to begin and the tank was placed in to the 
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container and packed with ice. The current was set at 300mA for 1 hour, after 
which the transfer process was stopped and the cassette holder(s) were 
removed. The cassette was opened removing the layers to retrieve the 
nitrocellulose paper which was then incubated with blocking buffer (5ml of 5% 
milk in PBS/Tween) for 1 hour at room temperature and then 4oC overnight.  
After the overnight incubation the nitrocellulose membrane was further exposed 
to 5% non-fat milk or 5% BSA (5% BSA was used for the detection of PDH-
pSer293) in PBS/Tween (0.05%) for 1 hour at room temperature. After the 
blocking step, membranes were washed with 5ml PBS/Tween (0.05%) twice and 
then incubated with the respective primary antibody for 1 hour at room 
temperature followed by overnight incubation on the shaker at 4oC. The primary 
antibodies used were:  
 PDH E1 phosphoserine 293, (Rabbit - Polyclonal) 1:3000 (1µl of anti-
body in 3,000 µl in 5% non-fat milk) (Novus Biologicals – Cambridge, UK)  
 PDK-1 (Rabbit - Polyclonal), 1:2,500 (1µl of anti-body in 2,500 µl in 5% 
non-fat milk (Novus Biologicals – Cambridge, UK) 
 PDH E1 (Mouse – Monoclonal), 1:5000 (1µl of anti-body in 5,000 µl in 
PBS/Tween (0.05%)) (Invitrogen – Paisley, UK) 
 β-Actin (Rabbit - Polyclonal), 1:10,000 (1µl of anti-body in 10,000 µl in 
5% non-fat milk) (Abcam – Cambridge, UK) 
 
After exposing the nitrocellulose membrane to the primary antibody the 
membranes was washed (5% BSA) and the next step was to expose the 
membrane to the secondary antibody. Secondary antibody (anti-rabbit or mouse 
depending on Ab) at the desired dilution (1:35000) in the 5% blocking buffer was 
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added followed by incubating the membrane with the secondary antibody on 
shaker for 1 hour at room temperature. The secondary antibody was removed, 
replaced with 5ml of PBS/TWEEN (0.05%) (15 minutes) and placed on the 
shaker at room temperature. This step was repeated a further two times.  
Commencing the second wash the nitrocellulose membrane was placed in a 
clean container and incubated with 600µl ECL reagent (300µl of ECL reagent A 
to 300µl of ECL reagent B) for up to a minute. Carefully removing the 
nitrocellulose membrane followed by removing excess ECL reagent, the 
nitrocellulose membrane was then placed in to a developing cassette. The 
nitrocellulose membrane was placed between two clear pieces of film. 
 
To develop the nitrocellulose membrane, the following was carried out in the 
dark room. The red light was turned on and measures were taken to minimise 
exposure to light, the developing film was cut approximately the same size of 
the membrane, and placed over the nitrocellulose membrane followed by closing 
the developing cassette for up to 2 minutes. After the 2 minute incubation the 
developing film was removed and placed in a tray with the developer (50ml 
developing solution to 450ml tap water) for up to 3 minutes. The developing film 
was washed with water to remove any developer. Placing the membrane in the 
fixing solution (75ml fixing solution to 425ml tap water) for 2 minutes then rinsing 
the developing film in water thoroughly to remove all traces of fixing solution, 
leaving it to dry. All experiments were carried out in triplicates.  
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Detecting apoptosis induced by Etoposide, DCA and Gossypol using 
Annexin-V FITC kit and FACS analysis 
HCT116 p53+/+ and HCT116 p53-/- cells were seeded at 1x105 cells per well (in 
a six well plate) and incubated for three days at 37oC in a 5% CO2 humidified 
atmosphere. On day three, cells were treated with Etoposide alone (10µM – 
0.625µM using a 2 fold dilution factor), DCA alone (250mM), Gossypol alone 
(5mM) and Etoposide (10µM – 0.625 µM) in combination with DCA (250mM) or 
Gossypol (10mM) for 24 hours and 48 hours. Apoptosis was detected using the 
Annexin-V-FLUOS staining kit (ROCHE, UK). Further experiments were 
conducted with DCA at 50mM and 100mM with exposure times of 24 hours and 
48 hours and apoptosis was detected using the Annexin-V-FLUOS staining kit. 
Following drug treatment, detached cells were harvested by collecting the 
medium and attached cells were harvested by trypsinisation as described 
previously. Detached and adherent cells were pooled and all cells were spun 
down for 3minutes at 800g. The supernatant was discarded, and this step was 
repeated again with 5ml of PBS only. To each sample, equal parts (2 µl) of 
Annexin V-Fluos labelling reagent (solution A) and Propidium Iodide solution 
(solution B) was added in a total volume of 100µl (incubation buffer) and 
incubated for 10min at room temperature. Each sample was placed in an 
individual FACS analysis tube and a further 400µl of incubation buffer was 
added to each sample and mixed. The samples were analysed by FACS 
analysis (BD Biosciences (Oxford UK)). All experiments were carried out in 
triplicates. 
FACS analysis generated raw data which was analysed using WIN-MDI-2.9 
provided by Bio-SoftNet Research Tools (http://www.mybiosoftware.com). The 
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data was presented as a DotPlot graph (figure 2.4). The data was gated to see 
the four different populations present in the sample and four areas were selected 
as presented below: 
 
 
 
Figure 2.4: A schematic diagram of a DotPlot graph which represents data 
obtained from FACS analysis after staining with Annexin V displaying different 
population of cells having undergone different stages of apoptosis after drug 
exposure. 1 = Top Left = Mechanically damaged cells, 2 = Top Right = 
Necrotic/Late apoptotic cells, 3 = Bottom Left = Viable cells and 4 = Bottom 
Right = Apoptotic cells represent the different populations of cells detected.  
 
Three populations of cells were observed: (1) viable cells: Annexin V-FITC 
negative and PI negative; (2) apoptotic cells: Annexin V-FITC positive and PI 
negative; (3) late apoptotic cells/necrotic cells: Annexin V-FITC positive and PI 
positive. Early apoptotic cells are stained by Annexin V but not PI because 
plasma membranes are intact while externalizing Annexin V. Late apoptotic and 
necrotic cells are stained by both PI and Annexin V as late apoptotic cells 
Top Right = Necrotic/Late apoptotic cells 
Bottom Right = Apoptotic cells 
Top Left = Mechanically damaged cells 
Bottom Left = Viable cells 
 
1 2 
3 4 
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because cells have ruptured membranes. Ruptured cells will stain double 
positive as the PI can enter the cell and Annexin V can stain exposed 
phosphatidylserine within the membrane. 
Influence of Glutamine on the growth of cancer cell lines 
In addition to the isogenic human colon colorectal carcinoma cell lines HCT116 
p53+/+ (wild type) and HCT116 p53-/- (null type) cell lines described previously, 
additional cell lines were used. These included MDA-MB-231 (human breast 
cancer cell line, ATCC HTB-26), MDA-MB-453 human  (breast cancer cell line, 
ATCC HTB-131), MCF7 (human breast cancer cell line, ATCC HTB-22), T-47D 
(human breast cancer cell line, ATCC HTB-133), and A549 (human lung cancer 
cell line, ATCC CLL-185), all of which were obtained from the American tissue 
culture collection (ATCC). In addition, TK10 human kidney renal Cell Carcinoma 
were also used but these cells were obtained from the DCTD Tumour Repository 
(http://dctd.cancer.gov). All cell lines were cultured in RPMI 1640 culture 
medium, supplemented with 10% foetal bovine serum and 1% sodium pyruvate 
(1mM) and L-glutamine (2mM).  
To determine the effect of glutamine deprivation on cell growth, complete 
medium (500ml without any glutamine supplement) was treated with 
glutaminase (Glutaminase from Escherichia Coli - 1 unit, Sigma Aldrich, UK) at 
room temperature for 1 hour followed by 1 hour incubation at 60oC to inactivate 
the glutaminase enzyme. Glutaminase was added to eliminate any traces of 
glutamine in the RPMI 1640 and in the serum. Media depleted of glutamine was 
supplemented with defined concentrations of glutamine ranging from 2mM- 
0.0039mM using a 2 fold dilution. For each cell line, 5x104 cells were added to 
 66 
 
T25 flasks containing 10 ml of medium supplemented with different 
concentrations of glutamine. Flasks were incubated at 37˚C in a 5% CO2 
humidified atmosphere for 4 days followed by trypsinisation and cell counting for 
each individual cell line. Visible changes in cellular morphology were also 
recorded at this stage.   
 
Rescue of cells following glutamine depletion studies 
For each cell line (HCT116 p53+/+, HCT116 p53-/-, MDA-MB-231, MDA-MB-453, 
MCF7, T-47D, A549 and TK10) a 1x106 cells/ml cell suspension was made in a 
final volume of 10ml. Cells were seeded into a T25 flask at a density of 5x104 
cells. A total of 16 T25 flasks were seeded per cell line and incubated at 37˚C in 
a 5% CO2 humidified atmosphere. For each day (days 1-8) T25 flasks were 
paired up, the first flask was used for the cell count (as mentioned in chapter 1 
method and materials) to determine the effect of glutamine depletion and the 
second flask had the RPMI 1640 without glutamine removed and replaced with 
complete RPMI 1640 (containing glutamine) to determine if the cells recovered. 
The second flask was incubated for a further 4 days at 37˚C followed by a cell 
count. 
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Results 
The response to cells following a continuous exposure to Gossypol  
The response of HCT116 p53+/+ and HCT116 p53-/- cells following continuous 
exposure to gossypol is presented in figure 2.5. Both HCT116 p53+/+ and 
HCT116 p53-/- cell lines were equally sensitive to gossypol with IC50 values 2.56 
+ 0.22mM and 2.72 + 0.29mM respectively. Response to gossypol is therefore 
independent of the p53 status. 
 
Figure 2.5:  Dose response curve following the continuous exposure of HCT116 
p53+/+ & HCT116 p53-/- cells to Gossypol. Each data point represents the mean 
± SD for three independent experiments. 
 
Response of cells following continuous and short term (1 hour) exposures 
to DCA 
The response of HCT116 p53+/+ and HCT116 p53-/- cells following continuous 
exposure to DCA in either RPMI 1640 or DMEM media is presented in figure 
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2.6. The response of HCT 116 cells in RPMI 1640 (panel A) to DCA was 
marginally higher (but not statistically significant, P>0.05) in HCT116 p53-/- cells 
compared to HCT116 p53+/+ with IC50 values of 16.53 ± 2.95mM and 13.92 ± 
2.74mM, respectively. The response of HCT116 cell lines maintained in DMEM 
culture medium (panel B) differed significantly (P < 0.05) from those obtained 
when cells were cultured in RPMI 1640. IC50 values for HCT116p53-/- and 
HCT116p53+/+ were 19.65 ± 0.42mM and 17.03 ± 2.65mM, respectively. 
The response of HCT116 p53+/+ and HCT116 p53-/- cells cultured in complete 
RPMI 1640 following 1 hour exposure to DCA is also presented in figure 2.5 
(panel A). The IC50 value for cell lines HCT116 p53+/+ and HCT116 p53-/- are 
248.20 ± 15.30mM and 263.97 ± 17.08mM, respectively. In DMEM however, no 
IC50 values were obtained following a 1 hour exposure (figure 2.5 panel B). Both 
HCT116 p53+/+ and HCT116 p53-/- cell lines did not respond to DCA in DMEM 
with IC50 values of greater than 500mM.  
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Figure 2.6: Dose response curves for continuous exposure and 1 hour 
exposure to DCA in HCT116 p53+/+ and HCT116 p53-/- cell lines. Cells were 
maintained in complete RPMI1640 (panel A) or DMEM culture medium (panel 
B). Each value represents the mean ± standard deviation for three 
independent experiments.   
 
The response of HCT116 cells to TKIs and Bortezomib 
The response of cells from cell lines HCT116 p53+/+ and HCT116 p53-/- following 
continuous exposure to the individual TKIs and Bortezomib is presented in figure 
2.7 and the IC50 values are reported in table 2. Both cell lines HCT116 p53+/+ 
and HCT116 p53-/- were sensitive to all the drugs and the IC50 values 
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demonstrated that cytotoxic activity was independent of the p53 status in all 
cases. Bortezomib was the most potent as it displayed IC50 values in nM 
concentrations whereas the TKIs typically displayed IC50 values in µM 
concentrations. 
The following data is presented in graphs, which displays the dose response 
curves for each individual TKI in response to HCT116 p53+/+ and HCT116 p53-
/- cell lines: 
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Figure 2.7: Dose response curves after exposure to TKIS’s and Bortezomib 
against HCT116 p53 +/+ (black lines) and HCT116 p53 -/- (red lines) cell lines. 
The exposure time for the drug was constant for 166 hours and each data point 
represents the mean ± SD for three independent experiments. 
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Figure 2.7: Dose response curves after exposure to TKIS’s and Bortezomib 
against HCT116 p53 +/+ (black lines) and HCT116 p53 -/- (red lines) cell lines. 
The exposure time for the drug was constant for 166 hours and each data point 
represents the mean ± SD for three independent experiments. 
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IC50 ± SD (µM) 
DRUG HCT116 p53 +/+ HCT116 p53 -/- P Value 
    
BORTEZOMIB 4.16 ± 0.21 (nM) 3.90 ± 0.27 (nM) 0.14 
SUNITINIB 2.98 ± 0.45 2.78 ± 0.07 0.26 
SORAFENIB 3.03 ± 0.74 3.18 ± 0.99 0.43 
NILOTINIB 4.36 ± 0.22 4.60 ±0.23 0.13 
VANDETINIB 9.13 ±2.69 10.68 ± 2.63 0.26 
DASATINIB 10.13 ± 3.29 9.11 ± 6.94 0.42 
MASITINIB 10.54 ± 1.37 9.00 ± 0.17 0.09 
IMATINIB 14.33 ± 1.88 13.96 ± 2.31 0.42 
GEFITINIB 14.74 ± 0.87 15.32 ± 1.10 0.26 
 
Table 2: The table presents the IC50 values obtained from individual TKI’s and 
Bortezomib following continuous exposure to the HCT116 p53+/+ and HCT116 
p53-/- cells. Each value represents the mean ± standard deviation from at least 
three independent experiments. Statistical analysis was carried out and a P 
value more than 0.05 indicates no significant differences in response to the two 
cell lines. 
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The response of cells to DCA combined with TKIs or Bortezomib 
To study the effect of TKIs on the activity of DCA, the IC50 value for the TKI and 
a range of DCA concentrations (0.976mM to 500mM) were used. The control 
using TKIs only were used to calculate percent survival and dose response 
curves for DCA alone and DCA plus TKI were drawn on the same axis (figure 
2.8).  
In HCT116 p53+/+ cells, IC50 values obtained from combinations of DCA and 
Masatinib, Bortezomib, Sunitinib, Dasatinib, Vandetanib did not significantly 
differ from IC50 values for DCA alone. In the HCT116 p53-/- cells, IC50 values 
obtained from combinations of DCA plus Sorafenib and Vandetanib did not 
significantly differ IC50 values for DCA alone. In contrast IC50 values from 
combinations of DCA and Imatinib, Gefitinib, Nilotinib and Sorafenib were 
significantly different from DCA alone in HCT116 p53+/+ cells. Similarly, IC50 
values from combinations of DCA and Imatinib, Gefitinib, Nilotinib, Bortezomib, 
Sunitinib and Dasatinib were significantly different from DCA alone in HCT116 
p53-/- cells. In these cases, the TKI’s did potentiate the activity of DCA. 
Furthermore, Sorafenib plus DCA displayed activity that was dependent of the 
p53 status with potentiation only seen in the HCT116 p53+/+ cell line. 
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Figure 2.8: Dose response curves measuring the effect of DCA alone and 
in combination with TKIs. The red symbols and lines represent data for 
HCT116 p53+/+ and the black symbols and lines representing HCT116 p53-/- 
cells. The red diamond and black square represent cells treated with DCA only. 
The red square and black circle represent cells treated with combinations of TKI 
(at the IC50 – please refer to table 2) and DCA (various doses). Each data point 
represents the mean ± SD for three independent experiments.  
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Figure 2.8: (Continued) Dose response curves measuring the effect of 
DCA alone and in combination with TKIs.  
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 IC50 (mM)  
DRUG 
TREATMENT 
HCT116 p53 
+/+ 
P Value HCT116 p53 
-/- 
P Value 
DCA (ALONE) 13.92 ± 2.74  16.53 ± 2.95  
DCA + 
SORAFENIB 
4.81 + 0.18 0.005* 16.95 + 1.15 0.0007* 
DCA + NILOTINIB 7.81 + 0.41 0.008* 7.44 + 0.23 0.010* 
DCA + GEFITINIB 9.60 ± 0.87 0.007* 9.56 ± 1.10 0.010* 
DCA + IMATINIB 10.80 ± 1.88 0.0158 10.30 ± 2.30 0.0142* 
DCA + MASITINIB 11.16 ± 1.37 0.011 10.55 ± 0.17 0.013* 
DCA + 
BORTEZOMIB 
12.42± 0.21 0.045* 13.68± 0.27 0.030* 
DCA + SUNITINIB 14.14 + 2.47 0.16 12.83 + 2.23 0.075 
DCA + DASATINIB 14.74 ± 3.29 0.069 12.62 ± 6.94 0.019* 
DCA + 
VANDETINIB 
15.49 + 2.90 0.37 14.28 + 1.94 0.15 
     
Table 3: Summary of IC50 values for DCA alone and DCA in combination with 
TKI’s. Each value represents the mean ± standard deviation for three 
independent experiments. Statistical analysis was conducted using a student’s 
t-test comparing IC50 values for DCA treated cells against IC50 values for DCA 
plus TKI/Bortezomib treated cells. The asterix indicates statistically significant 
(P<0.05). 
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Western Blot Analysis 
Bradford Assay 
The calibration curve was established by preparing serial dilutions of bovine 
serum albumin (BSA) ranging from 0.03125mg/ml to 1mg/ml. A representative 
example of linear regression analysis used is presented in figure 2.9 and in this 
example, the formula y = 0.7586x – 0.0076 was generated. This was used to 
calculate protein concentrations in the cell extract.  
                               
 
 
 
 
 
 
 
 
Figure 2.9: Bradford assay calibration curve used to determine the unknown 
concentration of cell extracts. This is a representative example of a calibration 
curve used for one experiment. Calibration curves for every experiment were 
run alongside each unknown set of samples.   
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Detecting inhibition of PDK1 by DCA 
The inhibition of PDK1 by DCA was determined by measuring the 
phosphorylation of PDH at serine 293. Western blot analysis of PDH, p-PDH 
and PDK expression in HCT116 cells following a 1 hour exposure to a range of 
DCA concentrations is presented in figure 2.10. DCA has no effect on the levels 
of PDH and PDK up to 250mM but at and above 250mM, DCA inhibits the 
phosphorylation of PDH at serine 293 in both HCT116 p53+/+ and HCT116 p53-
/- cells. DCA has no effect on the protein levels of PDH or PDK1 indicating that 
DCA is inhibiting the function of PDK1 at concentrations above 250mM following 
a one hour drug exposure.  
 
Figure 2.10: Western blot analysis of extracts from HCT116 p53 +/+ and 
HCT116 p53 -/- cells treated with a range of DCA concentrations for 1 hour. 
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Detecting apoptosis induced by therapeutic agents using Annexin-V FITC 
and FACS analysis 
The apoptotic response of HCT116 p53+/+ and HCT116 p53-/- to DCA, Gossypol 
and Etoposide alone and in combination (DCA with Etoposide and Gossypol 
with Etoposide) is presented figure 2.11 part A and B. The FACS analysis results 
were presented as percentage of the total population of cells that were 
undergoing apoptosis. The control consists of three conditions, the green bar 
represents no drug (solvent control – DMSO <0.1%) the red bar represents DCA 
only (at 250mM) and the blue bar represents Gossypol only (at 10mM). Under 
the control conditions, levels of apoptosis increased slightly in the presence of 
DCA alone or gossypol alone but the increase was minor and only approached 
significance in HCT 116 p53+/+ cells treated with gossypol (figure 3.9A). The 
remaining data demonstrates that as the concentration of etoposide alone 
increases, apoptosis increases reaching a maximum of 12.89 ± 03.56mM in 
HCT116 p53+/+ cells and 13.89 ± 0.29mM in HCT 116 p53-/- cells. There is 
therefore a dose dependent increase in apoptosis following treatment of cells 
with Etoposide.  
In the case of Etoposide combined with DCA (at 250mM), a similar dose 
dependent increase in apoptosis was observed but at 5 μM and 10μM 
Etoposide, a significant increase in apoptosis was observed compared to 
Etoposide alone. Similar results were obtained when Gossypol (at 10mM) was 
used in combination with Etoposide. These results demonstrate that combining 
Etoposide with either DCA or Gossypol enhances the activity of Etoposide in 
terms of inducing a greater apoptotic response (figure 2.11).  
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Figure 2.11: Induction of apoptosis following a 24 hour exposure to 
etoposide alone or etoposide in combination with DCA (250mM) or 
Gossypol (10mM). Panel A represents the response of HCT116 p53+/+ cells 
and panel B represents the response of HCT116 p53-/- cells. The control values 
represent drug vehicle alone (green bar), DCA alone (red bar) and Gossypol 
alone (blue bar). Each value represents the mean ± standard deviation for three 
independent experiments.  
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Induction of apoptosis in HCT116 cells following exposure to DCA alone  
The induction of apoptosis in HCT116 p53+/+ and HCT116 p53-/- cells following 
exposure to DCA is presented in figure 2.12 panels A-D. The data demonstrates 
that DCA induces apoptosis in both HCT116 cell lines in both a time dependent 
and p53 independent manner. Apoptosis was not readily detectable after 24 
hour exposure or 48 hour exposure of HCT116 p53+/+ cells to DCA (panel A). 
Similar results were obtained for HCT116 p53-/- cells (panel C). Cells that 
underwent late apoptosis/necrosis were detected after exposure to DCA and 
whilst there was no difference in the percentage of cells exhibiting late 
apoptosis/necrosis following a 24 hour exposure of HCT116 p53+/+ cells to DCA 
(panel B), a significant increase was seen following a 48 hour exposure to DCA 
(panel B). The level of induction of apoptosis/necrosis was similar for both doses 
of DCA tested. In HCT116 p53-/- cells (panel D), there was some evidence of a 
dose dependent increase in late apoptosis/necrosis following a 24 hour 
exposure to DCA.  Following a 48 hour exposure to DCA however, significant 
induction of late apoptosis/necrosis was observed in HCT116 p53-/- cells (panel 
D). 
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Figure 2.12: Induction of apoptosis is HCT 116 cells following exposure to 
DCA for 24 or 48 hours. Bar chart A presents the data for HCT116 p53+/+ cells 
following 24 hour and 48 hour exposure to DCA Bar Chart B presents the data 
for cells undergoing late apoptosis and necrosis following 24 hour and 48 hour 
exposure from DCA to cells from HCT116 p53+/+ cell line. Bar chart C presents 
the results for HCT116 p53-/- cells following 24 hour and 48 hour exposure to 
DCA. Bar Chart D presents the data for cells undergoing late apoptosis and 
necrosis following 24 hour and 48 hour exposure to DCA. Each value present 
the mean + SD for three independent experiments. 
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Influence of glutamine on the growth of cell lines in vitro 
The purpose of these experiments was to measure the effect of glutamine on 
the growth of a panel of cell lines HCT116 p53+/+, HCT116 p53-/-, MDA-MB-231, 
MDA-MB-453, MCF7, T-47D, A549 and TK10. The objective was to determine 
how much glutamine has to be removed from the media in order to halt cell 
growth and what happens to cells when glutamine is added to media following 
a period of glutamine depletion.  
 
The influence of glutamine depletion on the growth of cancer cells in 
vitro 
The effect different concentrations of glutamine have on the growth of a panel 
of cell lines is presented in figure 2.13. In all cases, the media was depleted of 
glutamine by treatment with glutaminase and the media was subsequently 
supplemented with defined concentrations of L-glutamine. After 4 days 
incubation in media, cells were trypsinised and counted. Cell growth was 
reduced in a glutamine dependent manner in all cases compare to controls 
(2mM Glutamine). The initial seeding density was 1 x 105 cells per flask and with 
the exception of A549 cells, the cell number in zero glutamine was below the 
initial seeding density indicating induction of cell death. Even in the presence of 
low levels of glutamine (3.9μM), cell density was comparable to the initial 
seeding density in all cases except A549 cells. A549 cells were the only cells 
tested that were able to grow in the absence of glutamine albeit at a reduced 
rate compared to controls.  
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Figure 2.13: A graph presenting a growth curve after exposure to varying 
concentrations of glutamine against a panel of cell lines. The graphs display 
the number of cells via cell count (taken 4 days after seeding) against the 
glutamine concentration. The bar graphs present individual means ± SD for 
three independent experiments. The initial number of cells seeded was 1 x 105 
per flask and the solid blue line represents the starting number of cells.  
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glutamine-depleted (glutaminase treated) media and incubated at 37oC for up to 
8 days. Every day, cells were trypsinised and cell number determined using the 
haemocytometer. In addition, changes in cell morphology occurring throughout 
the experiment were observed and recorded following visual inspection. The 
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results are presented in figures 2.14, in all cases, the number of cells attached 
to the base of culture flasks decreased significantly within 24 hours of seeding 
in glutamine-depleted media. Under these conditions, cell adherence was poor 
with large numbers of cells remaining in suspension. In contrast to the control 
cultures in glutamine rich medium, cell growth was significantly reduced in 
glutamine-depleted media. In all cases, cell growth, did occur up to day 4 or 5 
but after this, cell growth decreased with clearly visible signs of cell death 
observed under the microscope.  
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Figure 2.14: Growth curves measuring the effect of glutamine on a panel 
of cell lines. The graphs represent growth of cells in the presence and absence 
of glutaminase in the culture medium by cell count over a period of 8 days, day 
zero is when the cells were seeded. The bars to the left represent glutamine-
depleted (black) and bars to the right represent glutamine rich media (blue) 
respectively. Each data point represents the mean ± SD for three independent 
experiments.  
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Figure 2.14: (Continued) Growth curves measuring the effect of glutamine 
on a panel of cell lines.  
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Rescue of cell growth following glutamine depletion 
Cells were seeded at 1 x 105 cells per flask and incubated for up to 8 days in 
glutamine-deprived media as described above. Each day, the glutamine-
deprived media was removed and replaced with glutamine-rich media and cells 
were allowed to recover in this media for up to 4 days following which a cell 
count was performed. The results are presented in figure 2.15. Following a 1 
day incubation in glutamine-deprived media, cells rapidly recovered and good 
cell growth was observed. This was apparent for all cell lines tested. At the other 
end of the spectrum, no recovery was observed following an 8 day incubation of 
cells in glutamine-deprived media. At time intervals between these two 
extremes, the magnitude and timing of cell line recovery varied depending upon 
the cell line (figure 2.13). These results demonstrate that glutamine levels need 
to be reduced to low levels for long periods of time in order to induce a significant 
cytotoxic effect. Furthermore, replenishment of glutamine levels following a short 
period of glutamine depletion will lead to rapid repopulation of the cell 
population. A459 cells showed little effect to glutamine deprivation, although 
when the glutamine from the medium was removed A549 cells maintained 
proliferation but at a slower rate. Nevertheless, A549 cells continued to survive 
and proliferate unlike the other cell line (figure 2.13). 
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Figure 2.15: Recovery of cell growth following a period of glutamine 
depletion. Cells were incubated in glutamine-deprived conditions (black bars) 
and cell counts performed over a period of 8 days. At each stage of the growth 
curve, media was replaced with glutamine-rich media (red bars) and cells were 
allowed to recover for a further 4 days before cell number was determined. 
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Figure 2.15: (Continued) Recovery of cell growth following a period of 
glutamine depletion. Cells were incubated in glutamine-deprived conditions 
(black bars) and cell counts performed over a period of 8 days. 
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Discussion 
Whilst considerable progress has been made in reducing mortality in some types 
of cancer, mortality rates for other cancers remain high and there is a pressing 
need to develop novel therapeutic approaches. Understanding the biology of the 
disease and the pharmacology of drugs used to treat cancer is driving forward 
the development of novel anti-cancer drugs and novel strategies to discover new 
drugs and make existing drugs work better.  
The primary objective for this chapter was to see whether or not the Warburg 
effect can be pharmacologically manipulated to enhance the activity of targeted 
anti-cancer drugs. Specifically, inhibitors of LDH-A and PDK1 were evaluated in 
a panel of cell lines and combination studies in vitro conducted using a series of 
clinically approved tyrosine kinase inhibitors and Bortezomib. Glutamine 
addiction is also a common feature of the Warburg effect and a further objective 
was to determine what effect glutamine depletion strategies have on the viability 
and response of cells in vitro. The experimental studies investigated the ‘depth’ 
of glutamine depletion required to induce cellular responses and whether or not 
the effects of glutamine depletion are reversible once glutamine levels return to 
normal. The key results are discussed here in the context of the primary 
objective stated above.  
With regards to the cytotoxic activity of Gossypol and DCA alone, both proved 
to be cytotoxic to cells but only at doses that are typically much higher than 
cytotoxic drugs. To begin with Gossypol, a LDH A inhibitor was found to possess 
cytotoxicity activity against both HCT116 p53+/+ and HCT116 p53-/- cell lines in 
a dose dependent manner and independent of the p53 status. Ponzak et al 
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found that Gossypol is cytotoxic and does in fact induce cell death inhibiting 
cancer cell growth (Van Poznak et al., 2001). DCA is a known PDK1 inhibitor 
also possesses cytotoxicity against both HCT116 p53+/+ and HCT116 p53-/- cell 
lines in a dose dependent manner and independent of the p53 status. 
Michelakis et al (2008) found that DCA is cytotoxic to the cells which results in 
inhibition of cancer cell growth and proliferation (Michelakis et al., 2008). 
Working on HCT116 cells which are p53 wild type (+/+) or null (-/-) is an important 
aspect of the study as the p53 plays a key role in apoptosis pathway. The p53 
status is also important as p53 is implicated in many metabolic pathways and 
therefore an important aspect in research. The IC50 values for Gossypol and 
DCA clearly indicate they both induce cell death or inhibition of cell growth and 
are independent of the p53 status. The p53 tumour suppressor gene is mutated 
in over 50% of human tumours and plays an important role in the response to 
genotoxic stress and hypoxia (Vogelstein et al., 2000). p53 responds to 
upstream signals by activating transcription of genes important for cell cycle 
arrest, DNA repair, and apoptosis (Kaeser et al., 2004). It is therefore somewhat 
surprising that no differences in IC50 occurred following exposure to Gossypol 
and DCA but the data clearly indicates that response is independent of p53.   
To demonstrate that the dose of DCA used caused inhibition of PDK1, HCT116 
cell lines were analysed using the Western blot method to detecting specific 
proteins of interest. These were PDH, phosphorylated-PDH (p-PDH) and PDK1. 
The Western blots confirmed that at higher doses of DCA (250mM and 500mM) 
PDK1 was inhibited resulting in a reduction in p-PDH levels consistent with 
reactivation of PDH. These results are consistent with previously published 
studies (Cao et al., 2008). Following a 1 hour exposure to DCA, the dose of DCA 
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required to induce cytotoxic effects (figure 2.6) is directly comparable to the dose 
required to inhibit PDK1 (250mM). Whether the induction of cytotoxic effects is 
due to inhibition of PDK only is unclear and further studies would be required to 
determine this. Nevertheless, these results confirm that DCA alone is cytotoxic 
to cells in vitro (Heshe et al., 2011; Michelakis et al., 2008) and confirm that DCA 
is inhibiting PDK1 at doses that correlate with cytotoxic activity.  
 
Having demonstrated that Gossypol and DCA are cytotoxic in vitro, the next 
point of investigation was to confirm whether Gossypol and DCA possess the 
ability to reactivate apoptosis. Using Annexin-V fluorescent staining, exposure 
of cells to Gossypol or DCA resulted in the reactivation of apoptosis (figure 2.11).  
These results are consistent with other studies. Volate et al and Madhok et al 
reported that Gossypol and DCA can both reactivate apoptosis in cancer cells 
(Madhok et al., 2010; Volate et al., 2010). In contrast to Gossypol, FACS 
analysis demonstrated that DCA induced a significant number of necrosis in 
comparison to apoptosis (figure 2.12). An explanation for this, is in the 
understanding of the three populations of cells, which were observed in figure 
2.4: (1) viable cells: Annexin V-FITC negative and PI negative; (2) apoptotic 
cells: Annexin V-FITC positive and PI negative; (3) late apoptotic cells/necrotic 
cells: Annexin V-FITC positive and PI positive. Early apoptotic cells are stained 
by Annexin V but not PI because plasma membranes are intact while 
externalizing Annexin V. Late apoptotic and necrotic cells are stained by both PI 
and Annexin V because cells have ruptured membranes. Ruptured cells will 
stain double positive as the PI can enter the cell and Annexin V can stain 
exposed phosphatidylserine within the membrane (Wlodkowic et al., 2011).  
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As a single agent, DCA has proven to have anti-tumour efficacy in preclinical 
models (Michelakis et al., 2008) and is in clinical trials. Its principle application 
may, however, be in combinations of DCA with other drugs. DCA is known to 
affect a cells ability to undergo apoptosis. DCA is known to potentiate the activity 
of certain drugs e.g. Temozolomide (Michelakis et al., 2010), Doxorubicin 
(Heshe et al., 2011) and platinum based drugs (Olszewski et al., 2010) but no 
studies have assessed whether DCA can influence the activity of TK inhibitors 
or Bortezomib. RTKs are an integral part of cancer cell progression and 
contribute to the Warburg effect. To determine whether combinations of DCA 
and targeted therapeutics results in greater efficacy, this study first of all 
characterised the response of cell lines to TKIs and Bortezomib as single 
agents. The results demonstrated that Bortezomib was the most potent 
compound tested having cytotoxic effects on the cell in nM concentrations 
whereas, the TKIs were all active in the µM range. TKIs and Bortezomib as 
single agent drugs were equally cytotoxic to both HCT116 p53+/+ and HCT116 
p53-/- cell lines demonstrating that the activity of TKIs and Bortezomib is 
independent of the p53 status. p53 has been known to influence the response 
of chemotherapeutic agents leading to resistance (Brown and Wouters, 1999; 
Fridman and Lowe, 2003). It is well documented that the p53 plays a major role 
in apoptosis and due to mutations deficient p53 cells gain an advantage, losing 
the ability to induce apoptosis a hallmark of cancer (Kaufmann and Earnshaw, 
2000). Re-establishing apoptosis in cancer cells can lead to inhibition in cell 
growth and proliferation reducing tumour size (Zhang et al., 2000) therefore the 
influence of p53 is an important consideration in this research.  
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TKIs and Bortezomib in combination with DCA reduced the IC50 of DCA when 
compared to DCA alone. HCT116 p53+/+ and HCT116 p53-/- cells displayed 
differential cytotoxicity to different TKIs and Bortezomib alone, in combination 
with DCA enhanced potentiation was seen in selective TKIs and Bortezomib. 
Furthermore, TKIs and Bortezomib improved the efficacy of DCA when 
combined with some but not all of the TKIs and Bortezomib. Exposure to DCA 
in the presence of Bortezomib, Sorafenib, Masitinib, Imatinib and Gefitinib to 
cells from cell line HCT116 p53+/+ showed synergy, the IC50 values reported 
showed a decrease in IC50 values when compared to DCA alone (Table 3). In 
respect to the dose response curves a shift to the left was observed suggesting 
that the presence of the TKIs in combination potentiated the effects of DCA. As 
for the HCT116 p53-/- cell line, exposure to the TKIs and Bortezomib combined 
with DCA (except Sorafenib) produced lower IC50 values when compared with 
the IC50 value of DCA alone.  Bortezomib was the most potent of the drugs 
screened in this chapter as IC50 values obtained were in nM concentrations 
when exposed alone. The IC50 values obtained illustrated that the p53 status of 
the HCT116 cell lines did not influence the inhibitory effects of DCA and TKIs or 
Bortezomib in combination except for Sorafenib (figure 2.8 and table 3). 
Sorafenib displayed IC50 values that indicated that the p53 status of the HCT116 
may play a role in respect to toxicity. The mechanistic basis for this is not known 
however and further studies are required to explore the p53 dependent effects 
observed in this study.  
In summary, the results of this study have demonstrated that the combination of 
TKI’s or bortezomib with DCA can significantly influence the activity of DCA. This 
is the first time a potential link between the Warburg effect and the activity of 
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drugs targeted at aberrant cell signalling pathways has been demonstrated. 
Further studies are required to optimise the combination conditions and to 
understand the mechanistic basis underpinning these results. Nevertheless, 
they suggest that modulators of cellular metabolism could help existing drugs 
work better.   
 
Moving on to look at cancer cells addiction to glutamine, the aim was to critically 
evaluate whether glutamine depletion strategies have potential therapeutic 
applications. This research addressed many of the key issues relating to the 
‘depth’ of glutamine depletion required to induce cellular responses and whether 
or not the effects of glutamine depletion are reversible once glutamine levels 
return to normal.  
A variety of human cancer cell lines have shown sensitivity to glutamine 
starvation, including pancreatic cancer, glioblastoma multiforme, acute 
myelogenous leukemia, and small cell lung cancer (Wise and Thompson, 2010). 
Studies have detected an up-regulation of high affinity glutamine transporters in 
cancer (Fuchs and Bode, 2005). To understand the effects of glutamine on 
various cell lines this chapter investigated the response of cells to varying 
concentrations of glutamine over a period of 1-8 days. The data suggested that 
as the concentration of glutamine is reduced, the rate of proliferation is also 
reduced suggesting that lack or absence of glutamine does alter the proliferation 
and growth of cancer cells. These results support the notion that that cancer 
cells do require glutamine and the presence glutamine is an important driver of 
cancer cell proliferation. It also supports the notion that depriving cancer cells of 
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glutamine will impact upon their ability to proliferate and it therefore a potential 
therapeutic strategy. 
Growth curves for cells maintained in glutamine free medium demonstrated that 
the depletion of glutamine impacts the cells ability to proliferate in comparison 
to glutamine rich medium. Cells exposed to culture medium with no glutamine 
resulted in low cell counts and many of the cells dying on progressive days. On 
the other hand cells maintained with glutamine presented normal growth as the 
number days increased the cell count for each day increased. Cells 
demonstrated an addictive behaviour towards glutamine, which was observed 
in the panel of cell lines. The cells were observed under the microscope, after 
days 2/3 the cells from HCT116 cell lines displayed a change in cell morphology 
and further went on to lose adhesion. 
Furthermore, the panel of cells lines where starved of glutamine followed by 
reintroducing glutamine. Lack of glutamine resulted in decreased proliferation 
and lead to cell death but cells responded by recovering and returned to growth 
when glutamine was re-introduced. This experimental data further reinforces the 
fact that cancers cells are indeed addicted to glutamine (Daye and Wellen, 
2012). After days 4/5 depending on the cell line, cells maintained without 
glutamine were more susceptible to cell death and upon re-introduction of 
glutamine the cells were no longer able to proliferate and sustain growth. Cells 
reintroduced to glutamine before days 4/5 go on to recover and progressively 
continue to grow in numbers. Research carried out by Mariia et al. and her 
research team found that normal cells are also dependent on glutamine. They 
used normal human diploid human lung fibroblasts IMR-90, normal diploid 
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human foreskin fibroblasts and found that a deficiency in glutamine killed most 
of the human cells (Yuneva et al., 2007). 
In relation to glutamine and its role in cancer this chapter has provided 
experimental data which is in broad agreement with current literature (Reinert et 
al., 2006; Yuneva et al., 2007). The fact that cytotoxic effects were only observed 
after prolonged glutamine depletion does raise some concerns about the 
effectiveness of this approach as a single agent strategy. If glutamine has to be 
kept at low levels for such prolonged periods of time, it’s unclear what effect this 
would have on normal cells. Toxicity is therefore likely to limit the effectiveness 
of glutamine depletion strategies (Yuneva et al., 2007). In addition, glutamine 
levels have to reduce to very low levels in order to see cytotoxic effects. This is 
also a concern as it will be difficult to deplete glutamine levels below the 
concentrations required to kill cells. Nevertheless, glutamine depletion could be 
valuable when combined with other approaches being developed to target 
glutamine metabolism and it should be investigated further.  (DeBerardinis and 
Cheng, 2010; Wise and Thompson, 2010). 
 
Future research 
There are aspect of this research which can be exploited further, the current 
research looks at DCA in combination with TKIs yet there is scope for the 
combination of TKIs with Gossypol. Furthermore, Gossypol and DCA can be 
exposed to a panel of cell lines to see whether the toxicities are specific to 
certain cancer type or general to all cancers types.  
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In terms of combination studies, potential research avenues in the future could 
be switching the parameters between DCA and TKIs. DCA was the variable drug 
and the TKIs and Bortezomib were constant in this study. By making the TKIs 
and Bortezomib the variable drug and DCA as the drug which is kept constant, 
improved IC50 values could be achieved. The experimental data from the 
combination studies between DCA and TKIs looked promising, it would be 
beneficial if the cells underwent detection for apoptosis. This would provide data 
on the mechanism by which the drugs may induce cell death, if in fact the 
combination of drugs reactivated apoptosis.  
 
Moving on to the experimental data for the glutamine experiments, visual 
observations from the microscope showed that after a certain number of days 
either day 4/5 depending on cell line, cells maintained without glutamine were 
more susceptible to cell death and upon re-introduction of glutamine the cells 
were no longer able to proliferate, the reason behind these observations are still 
unclear and will need investigating. In the presence of no glutamine, cells were 
losing adhesion capability and also the morphology of cancer cells changed an 
aspect which could not be explained. Therefore investigating these unknowns 
would help understand the effect of glutamine in cancer cells and why the 
withdrawal of glutamine has such profound effects on adhesion and physiology. 
Furthermore glutamine inhibitors such as Kidrolase and Erwinase would be 
attractive in discovering the effect of glutamine deprivation on cells and the 
possible benefits to therapeutic outcomes and benefits to patients.  
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CHAPTER THREE 
 
 
 
 102 
 
Introduction 
Measuring the activity of Temozolomide analogues against MGMT and 
MMR deficient cell lines in the absence and presence of PaTrin2 
 
Alkylating drugs are the oldest class of anticancer drugs still commonly used 
and they play an important role in the treatment of several types of cancers. 
They are a class of chemotherapy drugs that bind to the DNA and prevent the 
process of DNA replication by directly damaging the DNA. Alkylation involves 
the addition of alkyl group to the N- and O- atoms in DNA bases. Methylation 
adducts at the N- terminal account for up to 80% methylated bases (Kondo et 
al., 2010). Since cancer cells in general, proliferate faster than healthy cells, 
cancer cells are more sensitive to DNA damage. There are different classes of 
alkylating agents, including: 
 Nitrogen mustards: such as mechlorethamine, ifosfamide, and Melphalan 
 Nitrosoureas: which include streptozocin, carmustine (BCNU), and 
lomustine 
 Alkyl sulfonates: busulfan 
 Triazines: dacarbazine (DTIC) and Temozolomide (Temodar) 
 Ethylenimines: thiotepa and altretamine (hexamethylmelamine) 
However, alkylating agents are also inherently toxic to normal cells, leading to 
damage in healthy normal cells. The damage is particularly acute in normal cells 
that divide frequently, such as those in the gastrointestinal tract, bone marrow, 
testicles and ovaries. By virtue of the fact they cause damage to DNA at sub-
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lethal doses, most of the alkylating agents are also known to be carcinogenic 
(Kondo et al., 2010). 
The development of Temozolomide (TMZ) started with Mitozolomide (MTZ) 
which is an imidazotetrazine. The imidazotetrazine ring is an acid stable 
precursor and prodrug of highly reactive alkyl diazonium ions that ultimately 
leads to DNA damage via methylation. 
 
 
Figure 3.0: Schematic diagram (A) for the mechanism of action of 
Temozolomide and Mitozolomide (B). Temozolomide is converted in to MTIC 
which methylates the DNA resulting in DNA nicks. Due to the DNA being 
damaged the cell induces apoptosis (Ramirez et al., 2013). Mitozolomide is 
converted in to chloroethyl-diazoniumion which alkylates the DNA resulting in 
apoptosis (Fang et al., 2012).  
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MTZ is a prodrug that spontaneously decomposes to a highly reactive DNA 
cross linking metabolite. MTZ can either bind two DNA molecules together or 
can bind at two different sites on the same DNA molecule making it an effective 
anti-cancer drug. MTZ had broad spectrum activity against many tumours and 
by Fiebig et al and his team identified the potential benefits of MTZ including 
curing some tumours (Fiebig, Berger et al. 1990). Despite the fact that MTZ 
could cure many of the mouse tumour models, clinical trials were terminated 
when toxicities were seen including prolonged and irreversible bone marrow 
toxicity, thrombocytopenia which causes bleeding into the tissues, bruising, and 
slow blood clotting after injury. Following these disappointing results with MTZ, 
the search for other analogues of MTZ continued looking to retain its good anti-
tumour activity but without the toxicity ultimately leading to the development of 
TMZ (Friedman et al., 2000).  
 
The story of TMZ began in the late 1970s, when Professor Stevens also known 
as the father of TMZ. Professor Stevens worked at Aston University developing 
new anti-cancer drugs against cancer. By the late 1980s he and his team 
developed a promising candidate, which later came to be known as 
Temozolomide (Sansom, 2009). After a long process of development, TMZ was 
approved for clinical trials at Charing Cross Hospital in London. Results from 
these clinical trials with TMZ showed promising results which lead to Cancer 
Research UK supporting further clinical trials in a greater number of cancer 
patients. The results showed that the drug could bring significant benefits to 
patients with brain tumours. As well as extending survival, patients with 
glioblastoma benefited mentally and physically from treatment with TMZ due to 
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reduced toxicity. The drug then progressed to the next stage involving much 
larger phase III trials. After much success, Cancer Research UK helped license 
the drug leading to the approval of TMZ for use in clinic (Clarke et al., 2010).  
 
In 2001, NICE (the National Institute of Health and Care Excellence) ruled that 
TMZ could be used for “second line” therapy for people with brain tumours that 
had come back after treatment. In 2006 the results of the major large scale 
phase III trial of TMZ alongside radiotherapy for people with glioblastoma brain 
tumours were announced (Guilfoyle et al., 2011; Mirimanoff et al., 2006). The 
results found that the drug could bring significant increases in survival in patients 
with aggressive tumours. As a result of larger trials (Mirimanoff et al., 2006), 
TMZ was approved by NICE as a front line drug for people newly diagnosed with 
brain tumours in 2007, and has now been used to treat thousands of patients 
around the world.  
 
TMZ is a prodrug that undergoes spontaneous decomposition in solution at 
physiological pH to the reactive intermediate 5-(3-methyl-1-triazenyl)imidazole-
4-carboxamide (MTIC), which forms a reactive alkyl diazonium ion that 
methylates the N7 and O6 positions of guanine and the N3 position of adenine 
(Tentori and Graziani, 2009). The methyl adducts, O6-meG, N7-meG, and N3-
methyladenine (N3-meA) result in deletion by the mismatch repair (MMR) or O-
6-methylguanine-DNA methyltransferase (MGMT) pathways that will lead 
eventually to cellular apoptosis (Fu et al., 2012) Therefore, TMZ exerts its 
chemotherapeutic efficacy in cancer cells by inducing cell death. However, 
acquired resistance to TMZ develops in cancer cells and been shown to 
participate in the limitation of therapeutic outcome. A large percentage of 
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tumours are resistant to the cytotoxic effects of the TMZ induced DNA lesion O6-
MeG due to elevated expression of MGMT or a defective MMR pathway. 
Whilst being an effective anti-cancer agent, inherent and acquired resistance to 
TMZ present major obstacles to successful treatment therefore necessitating 
the need for new and improved analogues that circumvent the drug resistance 
problem. To understand the mechanisms of resistance in cancer cells the next 
part of the chapter will focus on the two main types of resistance encountered 
by TMZ. This predominantly includes MMR and MGMT resistance mechanisms. 
 
MMR resistance in cells 
While most DNA replicates without any problems, mistakes do occur, with 
polymerase enzymes sometimes inserting the wrong nucleotide or too many or 
too few nucleotides into a sequence (Iyer et al., 2006). Fortunately, most of these 
mistakes are fixed through various DNA repair processes. DNA mismatch repair 
(MMR) is one of those systems for recognizing and repairing erroneous 
insertion, deletion, and miss-incorporation of bases that arise during DNA 
replication, as well as repairing DNA damage (Pray, 2008). 
The MMR system, attempts to repair the mismatch by removing the newly 
synthesised strand. However if the mismatch remains, DNA damage in the form 
of single and/or double-strand breaks are generated. The DNA strand breaks 
are detected by the G2/M check point in the replication cycle and this leads to 
the induction of apoptosis (Drabløs et al., 2004). Due to the loss of the MMR 
system the cell cannot detect DNA damage and therefore cannot activate 
apoptosis leading to drug resistance. The MMR proteins are involved in 
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mediating the activation of cell cycle checkpoints and apoptosis in response to 
DNA damage. MMR deficient cells have been reported to be resistant to the 
methylating agents such as TMZ. The human ovarian adenocarcinoma cell line 
A2780 is MMR proficient and expresses MLH1. The MLH1 (mutL homologue 1) 
protein, shown to be important in determining sensitivity to a number of important 
chemotherapeutic agents. Loss of MMR due to methylation of the hMLH1 gene 
promoter results in resistance in cancer. Methylation of the hMLH1 gene 
promoter is observed in many tumour types and is associated with clinical drug 
resistance (Plumb et al., 2004). A2780/Cis is MMR deficient and does not 
express MLH1 protein because of hypermethylation of the hMLH1 gene 
promoter region (Strathdee et al., 1999).  
 
MGMT resistance in cells 
MGMT mediated repair is unique among DNA repair pathways. It transfers the 
methyl group to an internal cysteine residue in the protein, acting as both a 
transferor and an acceptor of the alkyl group. MGMT removes the O6-
alkylguanine DNA adduct through covalent transfer of the alkyl group to the 
conserved active site, cysteine, and restores the guanine to normal (Tiwari and 
Mishra, 2009). After receiving a methyl group from O6-meG, MGMT is 
inactivated and subjected to ubiquitin mediated degradation. Overexpression of 
MGMT prevents cancer cells from death induced by alkylating agents with a 
correlation between MGMT activity and tumour drug resistance (Fan et al., 
2013). The protective role of MGMT against the cytotoxic effect of methylating 
drugs such as TMZ has been shown in human cell lines and human xenograft 
models (Gerson, 2002). 
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Therefore, investigation of potential drug interactions that modulate MGMT 
could help improve the efficacy of chemotherapies utilizing alkylating agents 
(Hegi et al., 2008). Inhibition of MGMT promotes antitumor activity of alkylating 
agents such as TMZ both in vitro and in vivo (Dolan et al. 1991; Wedge et al. 
1996). Epigenetic silencing of the MGMT gene in tumour cells by methylation of 
its promoter region has been associated with glioma sensitivity to alkylating 
chemotherapy in particular TMZ (Esteller et al. 2000). Having identified the 
mechanism of resistance, MGMT can be successfully inactivated by free 
guanine base derivatives, with alkyl groups at the O6 position, which act as 
“pseudo substrates” (McElhinney et al., 1998). PaTrin2 has been identified as 
MGMT in-activator and compared to TMZ as a single agent, the combination of 
PaTrin2 with TMZ has been shown to significantly decrease tumour growth 
(Middleton et al., 2000). Furthermore, PaTrin2 has entered phase II clinical trials 
and PaTrin2 plus TMZ combination is under clinical development in England 
demonstrating the potential therapeutic benefits (Clemons et al., 2005). Cancer 
Research UK carried out a Phase I clinical study of PaTrin2, which was 
completed in the early part of 2002. The study showed that the combination 
of PaTrin2 and Temozolomide was well tolerated. PaTrin2 can effectively inhibit 
MGMT with no toxicities observed other than those usually seen with TMZ alone 
(Rietschel et al., 2008). 
KuDOS Pharmaceuticals (KuDOS) of Cambridge, United Kingdom acquired a 
worldwide licence for PaTrin2. KuDOS then went on to pursue Phase II clinical 
trials with PaTrin2 in combination with Temozolomide against metastatic 
melanoma and advanced colorectal cancer in 2003 in partnership with Cancer 
Research UK.  To date there have been a number of research groups looking 
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at PaTrin2 and have published articles in support of the initial result showing that 
the combination of PaTrin2 and Temozolomide enhancing the antitumor 
activity overcoming MGMT/MMR resistance (Barvaux et al., 2004b; Clemons et 
al., 2005; Woolford et al., 2006). 
Over the years there has been a focus on utilising PaTrin2 in manipulating 
MGMT levels to enhance alkylating agent therapy. Research has focused on 
TMZ, which has presented resistance in many cancer types and therefore the 
development of PaTrin2 has been valuable. Much of the research carried out 
with TMZ and PaTrin2 has been in malignant brain tumours (Fan et al., 2013), 
and much success has been seen against MGMT resistance overcoming 
significant barriers in treatment (Hegi et al., 2008; Sharma et al., 2009). Current 
research, phase I and II clinical trials (Kefford et al., 2009; Rietschel et al., 2008) 
are looking to incorporate PaTrin2 in to standard treatments methods available 
for the treatment of patients with Gliomas amongst other cancer types.  
Current treatment for cancers such as glioblastoma multiforme (GBM), the most 
common and malignant brain tumour combines chemotherapy involving TMZ, 
radiotherapy and surgery. TMZ is an alkylating agent that induces apoptosis and 
is considered to be the frontline chemotherapeutic agent for treatment of GBM 
(Zhang et al., 2012). Despite TMZ being used as a frontline anti-cancer drug, 
GBM patients commonly exhibit resistance to TMZ treatment. Therefore a need 
for better and more improved chemotherapeutic agents may be one of the more 
productive avenues for improvement. This research is the first to use the novel 
EA02 drug compounds, which are TMZ derivatives developed in house (by Dr 
Richard Wheelhouse, School of Pharmacy). These compounds are novel and 
therefore the mechanism of action is unknown, due to their structural similarities 
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to TMZ it can proposed that the EA02 drug compounds act in the same way 
TMZ targets the DNA.  
 
The use of cell lines A2780 and A2780/Cis was important as the mutations 
possessed by the cancer cells will determine the outcome of the results 
obtained. The human ovarian adenocarcinoma cell line A2780 is MMR proficient 
and expresses MLH1, whereas A2780/Cis is MMR deficient and does not 
express MLH1 protein because of hypermethylation of the hMLH1 gene 
promoter region (Strathdee et al., 1999). Furthermore both cell lines A2780 and 
A2790/Cis express MGMT which contributes towards TMZ resistance (Barvaux 
et al., 2004b). In terms of properties for any potential analogue of TMZ it would 
have to possess in the context of MMR/MGMT resistance, the ability to induce 
lesions which are not recognised by MGMT. The screening process will hope to 
identify compounds that are not significantly potentiated by PaTrin2 (inactivation 
of MGMT by PaTrin2 should have little or no effect on activity). In the case of 
MMR, to identify compound that work or induce toxicity in both MMR proficient 
and MMR deficient cells. Therefore a compound which is toxic irrespective of 
cell line and the presence of PaTrin2, will be of interest. 
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Aims and objectives 
In summary, TMZ is a multi-billion dollar drug used to treat glioblastoma. Whilst 
effective, its efficacy is compromised by drug resistance mechanisms including 
deficiencies in MMR and over-expression of MGMT. Novel analogues of TMZ 
will be evaluated with the aim of identifying second generation compounds that 
retain the desirable properties of TMZ but have improved properties in terms of 
circumvention of the drug resistance mechanisms that have reduced the efficacy 
of TMZ. As stated previously, the search for new therapies represents a major 
strategy towards the treatment of cancer. New chemotherapies can be 
developed along target orientated principles or by developing analogues of 
successful drugs that have been engineered to provide solutions to problems 
encountered by the parent drug, Temozolomide. 
 
The specific aims of the work conducted in this chapter are listed below: 
4. To determine the activity of TMZ, MTZ, Cisplatin and Melphalan in the 
absence and presence of PaTrin2 against a panel of cell lines in vitro. 
5. To determine whether the activity of novel EA02 drug compounds can 
overcome MMR and MGMT resistance against a panel of cell lines in 
vitro. 
6. To determine whether inhibition by PaTrin2 increases sensitivity to TMZ, 
MTZ, Cisplatin, Melphalan and the novel EA02 drug compounds in vitro.  
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Methods and Materials 
 
Consumables 
All chemicals and drugs were purchased from Sigma Aldrich (Poole, United 
Kingdom) unless stated otherwise. All cell culture consumables were purchased 
from Corning (Amsterdam, The Netherlands). The EA02 compounds and 
PaTrin2 were provided by Dr Richard Wheelhouse (University of Bradford, UK)  
  
Cell Lines and Maintenance 
The A2780 and the Cisplatin resistant A2780/Cis human ovarian cancer cell 
lines were obtained from the European Collection of Animal Cell Cultures 
(ECACC). All cell lines were cultured in Roswell Park Memorial Institute 1640 
(RPMI 1640) culture medium, supplemented with 10% foetal bovine serum, 
sodium pyruvate (1mM) and L- Glutamine (2mM). Cells were maintained at 37˚C 
in a 5% CO2 humidified atmosphere until required for experimental use. For 
routine sub-culturing, cell counting, cell viability assays and the MTT assay, 
please refer to the methods sections in Chapter two.   
 
Measuring the response of cell lines to Temozolomide, Mitozolomide, 
Cisplatin and a range of EA02 compounds  
The response of A2780 and A2780/Cis following continuous exposure to a broad 
range of concentrations of Temozolomide (TMZ), Mitozolomide (MTZ), 
Melphalan and Cisplatin were determined using the MTT assay as described 
previously in Chapter 2. Similarly, the response of A2780 and A2780/Cis 
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following continuous exposure to EA02 drug compounds was determined using 
the MTT assay. A2780 and A2780/Cis cell lines were exposed to a broad range 
of drug concentrations for 6 days, details of which are presented in the results 
section. All compounds were initially dissolved in DMSO and the final 
concentration of DMSO was 0.1% (v/v) in all cases. As described in chapter 2, 
the results are expressed in terms of IC50 values and each experiment was 
repeated in triplicate.   
 
Combination studies to determine the effect of PaTrin2 on the activity of 
TMZ, MTZ, Melphalan, Cisplatin and EA02 compounds   
The response of A2780 and A2780/Cis following continuous exposure to TMZ, 
MTZ, Cisplatin, Melphalan and EA02 drug compounds in combination with 
PaTrin2 was determined using the MTT assay. Details of the compounds used 
and their solubility is presented in table 4. A diluent was made consisting of 
complete RPMI 1640 culture medium plus PaTrin2 (10µM in DMSO). This 
diluent was used to make up the highest concentration of the compounds being 
tested and also used for making up the remaining 8 concentrations using a 2 
fold dilution. For combination studies there were variations from the standard 
chemosensitivity assays described previously. The first variation was the 
inclusion of an additional control. In addition to the routine drug free control, an 
additional control was included which consisted of cells exposed to PaTrin2 only. 
For the calculation of % cell survival, this second control was used to represent 
100% cell survival (ie response was normalised relative to the effect of PaTrin2 
alone). All cells were exposed to compounds (with or without PaTrin2) for 144 
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hours and response was determined using the MTT assay as described 
previously. Any deviation in the dose response curve from the drug alone 
experiments (i.e. no PaTrin2) indicates either antagonism or synergistic effects.  
 
Table 4: Compounds used for testing the effect of PaTrin2 on chemosensitivity.   
DRUG MOLECULAR 
WEIGHT 
SOLVENT USED TO 
SOLUBILIZE 
COMPOUNDS 
STOCK 
CONCENTRATION 
STORAGE 
Temozolomide 194.15 DMSO 100mM -20oC 
Mitozolomide 242.62 DMSO 100mM -20oC 
Cisplatin 300.05 DMSO 100mM -20oC 
Melphalan 305.20 WATER 100mM 4oC 
EA02-45 527.70 DMSO 10mM -20oC 
EA02-58 314.62 DMSO 100mM -20oC 
EA02-59 348.21 DMSO 100mM -20oC 
EA02-60 357.97 DMSO 100mM -20oC 
EA02-61 345.97 DMSO 100mM -20oC 
EA02-64 540.44 DMSO 20mM -20oC 
EA02-65 534.22 DMSO 20mM -20oC 
EA02-27C 628.54 DMSO 20mM -20oC 
PaTrin-2 333.37 DMSO 10mM -20oC 
 
*For information on the characterisation of the above compound please refer to 
the following article (Pletsas et al., 2013)  
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PaTrin2 
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Results 
The response of A2780 and A2780/Cis cells following continuous exposure to 
MTZ, TMZ, Cisplatin, and Melphalan in the absence and presence of PaTrin2 
are presented in figure 3.1 and table 5. Both A2780 and A2780/Cis cell lines 
were sensitive to all the drugs with a broad range of IC50 values obtained. TMZ 
did not achieve an IC50 when exposed to A2780 cells in the absence of PaTrin2 
but in the presence of PaTrin2, TMZ showed toxicity against the cell line A2780 
(IC50 = 17.22uM). The response of A2780 and A2780/Cis cells following 
continuous exposure to MTZ, TMZ, Cisplatin, and Melphalan in the presence of 
PaTrin2 generated a broad range of IC50 values. Some but not all the drugs were 
potentiated and for those of the drugs which were potentiated, a leftwards shift 
was observed in the dose response curve.  
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Figure 3.1: Response of A2780 and A2780/Cis cell lines to TMZ, MTZ, 
Melphalan and Cisplatin alone (solid black line-A2780, solid red line-A2780 in 
the presence of PaTrin2) and in combination with Patrin2 (dotted black line-
A2780/CIS, dotted red-A2780/CIS in the presence of PaTrin2). Each value 
represents a mean ± SD for three independent experiments. 
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Figure 3.1: (Continued) Response of A2780 and A2780/Cis cell lines to TMZ, 
MTZ, Melphalan and Cisplatin alone and in combination with PaTrin2. 
 
Table 5: Summary of IC50 values for drug alone and drug in combination with 
PaTrin2 
Drug A2780 IC50  
(drug only) 
μM 
A2780 IC50  
(drug + 
PaTrin2) 
μM 
A2780 Cis IC50 
(drug only) 
μM 
A2780 Cis IC50 
(drug + 
PaTrin2) 
μM 
Cisplatin 23.87±03.88 11.38±03.34 40.95±03.28 32.24±06.13 
Melphalan 16.84±01.47 14.50±05.59 36.05±06.08 15.99±03.07 
Mitozolomide 44.28±03.88 28.73±10.79 72.70±01.73 30.42±05.47 
Temozolomide >250 17.22±0.95 216.87±14.34 88.90±03.29 
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Response of A2780 and A2780/Cis to EA02 compounds 
The response of A2780 and A2780/Cis cell lines following continuous exposure 
to EA02 drug compounds in the absence and presence of PaTrin2 are presented 
in figures 3.2, figure 3.3 and table 6. In order of potency in response to A2780 
cell line, the drug compound EA02-64 was the most potent followed by EA02-
65, 45 and 27c with IC50 values of 2.66±2.85µM, 10.94±3.19µM, 11.27±2.40µM 
and 14.90±1.53µM respectively. The response to A2780/Cis cell line in order of 
potency were as follows: 3.06±1.93µM (EA02-65), 9.77±3.38µM (EA02-64), 
22.97±6.08µM (EA02-45) and EA02-27c no IC50 was obtained (>40µM). Over 
all A2780/Cis was more resistant to the EA02 drug compounds than A2780 cells 
(table 6). A2780 and A2780/Cis cell lines were sensitive to all the drug EA02 
drug compounds plus PaTrin2 with varying degrees of toxicity. In the presence 
of PaTrin2 cell lines A2780 and A2780/Cis showed greater sensitivity in 
response to EA02-45, 64, 65 and 27c with the exception of EA02-64, which did 
not achieve an IC50 value in response to A2780/Cis cell line. In the presence of 
PaTrin2 cell line A2780 showed greater sensitivity.   
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Figure 3.2: The response of A2780 and A2780/Cis cells following continuous 
exposure to EA02 compounds with or without PaTrin2. The black and red 
symbols and lines represent EA02 compounds only and EA02 plus PaTrin2 
respectively. The label on the Y axis denotes the cell line used and the X axis 
details the specific EA02 compound tested. Each value represents the mean ± 
standard deviation for three independent experiments.  
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Figure 3.2: (Continued) The response of A2780 and A2780/Cis cells following 
continuous exposure to EA02 compounds with or without PaTrin2.  
 
Table 6: Summary of IC50 values for drug alone and drug in combination with 
PaTrin2 
Drug A2780 IC50 
(drug only) 
μM 
A2780 IC50 
(drug + 
PaTrin2) 
μM 
A2780 Cis IC50 
(drug only) 
μM 
A2780 Cis IC50 
(drug + 
PaTrin2) 
μM 
EA02-27c 14.90±01.53 14.06±01.24 >40 12.28±02.66 
EA02-45 11.27±02.40 06.02±00.65 22.97±06.08 10.76±00.59 
EA02-64 02.66±02.85 10.53±00.64 09.77±03.38 >40 
EA02-65 10.94±03.19 12.94±01.94 03.06±01.93 13.10±01.72 
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The response of A2780 and A2780/Cis cells following continuous exposure to 
EA02 drug compounds EA02- 58, 59, 60, 61 and 66 is presented in figure 3.3. 
Both A2780 and A2780/Cis cells were sensitive to all the drugs with varying 
degrees of sensitivity. In the order of potency, EA02-59, 60, 66, 58 and 61 were 
the most potent against A2780 cells. Against A2780/Cis cells, EA02-61, 59, 60, 
58 and 66 were most potent. Both cell lines responded differently in response to 
EA02 drug compounds, A2780/Cis cells were more resistant compared to 
A2780 cells as IC50 values in response to A2780/Cis were higher in comparison 
to IC50 values in response to A2780 except EA02-61 (see table 7). None of the 
EA02 drugs mentioned above worked well against both cell lines. 
In the presence of PaTrin2 in order of potency EA02-66, 58, 59, 60 and 61 were 
potent in response to A2780 cells and in order of potency EA02-66, 60, 59 and 
58 were the most potent with the exception of EA02-61 where no IC50 values 
was obtained. A2780/Cis cells were more resistant than A2780 once again. In 
the presence of PaTrin2 IC50 values in response to A2780/Cis were higher in 
comparison to IC50 values in response to A2780 except EA02-61 (see table 7). 
PaTrin2 altered the response of cells to some but not all individual EA02 
compounds, in response to A2780 the following were potentiated by PaTrin2: 
EA02-58, 61 and 66 and in response to A2780/Cis the following were 
potentiated by PaTrin2: EA02-66, the remaining EA02 drug compounds 
produced higher IC50 values in the presence of PaTrin2 in comparison to EA02 
drug alone.  
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Figure 3.3: The response of A2780 and A2780/Cis cells following continuous 
exposure to EA02 compounds with or without PaTrin2. The black and red 
symbols and lines represent EA02 compounds only and EA02 plus PaTrin2 
respectively. The label on the Y axis denotes the cell line used and the X axis 
details the specific EA02 compound tested. Each value represents the mean ± 
standard deviation for three independent experiments.  
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Figure 3.3: (continued) The response of A2780 and A2780/Cis cells following 
continuous exposure to EA02 compounds with or without PaTrin2. 
 
Table 7: Summary of IC50 values for drug alone and drug in combination with 
PaTrin2 
Drug A2780 IC50  
(drug only) 
μM 
A2780 IC50  
(drug + 
PaTrin2) 
μM 
A2780 Cis IC50 
(drug only) 
μM 
A2780 Cis IC50 
(drug + 
PaTrin2) 
μM 
EA02-58 42.37±06.35 18.37±02.00 64.41±02.49 74.96±13.42 
EA02-59 15.81±04.49 25.31±04.62 32.47±05.06 64.76±04.12 
EA02-60 29.46±06.03 40.21±06.41 45.68±01.90 64.76±07.83 
EA02-61 73.25±10.22 43.98±09.64 21.54±02.80 >100 
EA02-66 31.63±02.76 5.46±00.08 72.69±12.04 15±03.29 
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Discussion 
The objectives set out for this chapter were to identify novel analogues of TMZ 
that circumvent the resistance mechanisms that limit the effectiveness of TMZ. 
As outlined in the introduction, the ideal compound would be one that induces 
cytotoxicity that is not MGMT dependent. In the screen, this would be identified 
as compounds that induces similar IC50 values in the presence and absence of 
the MGMT inhibitor PaTrin2. In addition, compounds that also work against 
MMR deficient cells (A2780/Cis) would be desirable. The results obtained in this 
chapter are discussed in the context of these requirements. 
The response from A2780 and A2780/Cis cells following continuous exposure 
to the drugs was measured via MTT assay. TMZ was non-toxic against A2780 
cells yet toxic against A2780/Cis cells, whereas MTZ, Cisplatin and Melphalan 
were all toxic to both cell lines A2780 and A2780/Cis. In the absence of PaTrin2, 
cells from cell line A2780/Cis demonstrated greater resistant to MTZ, Cisplatin 
and Melphalan in comparison to cell line A2780 (table 3.3). In the presence of 
PaTrin2 TMZ, MTZ, Cisplatin and Melphalan were all toxic and displayed 
potentiation when exposed to A2780 and A2780/Cis cell lines (please refer to 
table 5) demonstrating that the addition of PaTrin2 enhanced cytotoxic activity 
indicating a role for MGMT in the mechanism of action. In the absence of 
PaTrin2, TMZ did not induce toxicity but in the presence of PaTrin2, TMZ was 
able to achieve an IC50 value. This result is consistent with a role for MGMT in 
conveying drug resistance as has been described elsewhere in the literature 
(Hegi et al., 2008; Zhang et al., 2011). PaTrin2 has been found to potentiate the 
activity of certain drugs, found in the study conducted by Baravaux et.al. 
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(Barvaux et al., 2004a) reinforcing that it is a valuable drug in the fight against 
resistance and a drug with great therapeutic potential. In summary, inclusion of 
PaTrin2 in cell culture media potentiated the activity of MTZ, TMZ, Cisplatin and 
Melphalan with the most marked effect being observed in the case of TMZ. 
These results also provided evidence to validate the experimental conditions 
required to critically assess the activity of novel analogues.  
Compared to the A2780/Cis cell line, A2780 cells were more sensitive. IC50 
values obtained were higher in response to A2780/Cis compared to IC50 values 
obtained against cell line A2780.  
 
Some but not all EA02 drug compounds were of interest, as stated previously in 
the introduction in terms of properties for any potential analogue of TMZ it would 
have to possess in the context of MMR/MGMT resistance, the ability to induce 
lesions which are not recognised by MGMT. In the case of MMR, to identify 
compound that work or induce toxicity in both MMR proficient and MMR deficient 
cells. The following compounds were toxic in the absence of PaTrin2; EA02-45, 
59, 60, 64, 65 and 27c against cells from cell line A2780 (table 6 and 7). EA02-
45, 59, 61, 64 and 65 were toxic in the absence of PaTrin2 against cells from 
cell line A2780/Cis (table 6 and 7). From the range of EA02 drugs mentioned 
above, only a few of the drugs were effective in terms of overcoming MGMT 
resistance or did not require a MGMT inhibitor (PaTrin2). In terms of MMR 
resistance and looking for compounds which induced toxicity irrespective of 
deficient or proficient MMR, the following EA02 compounds were promising; 
EA02-45, 59, 64 and 65 producing toxicity irrespective of MGMT or MMR status. 
Therefore the aims of generating new TMZ like (imidazotetrazine) prodrugs with 
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activity independent of MGMT and MMR have been achieved via selected EA02 
drug compounds. 
Although we look to find and identify compounds which are not dependent on 
PaTrin2 current literature states that there is a use for PaTrin2. The synergistic 
effects of PaTrin2 are well documented in combination with TMZ, current 
research is looking to combine PaTrin2 with TMZ to achieve the optimum toxicity 
and where appropriate in conjunction with radiotherapy (Kefford et al., 2009).  
 
Future research 
The initial success of identifying and the development of EA02 drug compounds 
which have the desired characteristics in terms of overcoming MGMT/MMR 
resistance in the form of EA02-45, 59, 64 and 65 provides scope for testing on 
different cancer cell types/tumour types and observe how  tumour respond to 
such drugs. Furthermore the EA02 compounds can be tested against the 
HCT116 p53+/+ and HCT116 p53-/- cell lines to see whether the p53 status of cell 
influences the cytotoxic nature of these drugs.  
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Discussion 
Increasing evidence suggests that oncoproteins can directly reprogram tumour 
cell metabolism, rendering the cells addicted to certain nutrients in a way non-
transformed cells are not. However, whether alterations in cancer metabolism 
can be safely targeted therapeutically remains be determined. In chapter 2 of 
this thesis, the topic of interest focused on whether targeting key enzymes 
involved in the Warburg effect could circumvent resistance to apoptosis 
(conferred by cells switching to a glycolytic phenotype) and potentiate the 
activity of existing anti-cancer drugs. In addition, tumour cells become ‘addicted’ 
to glutamine as part of the Warburg effect and glutamine depletion studies were 
conducted to determine whether or not this strategy was a feasible option for 
therapeutic intervention. Finally, chapter 3 of this thesis addressed another 
major theme which was the evaluation of novel analogues of TMZ to identify 
analogues, which evade the key mechanisms that cause resistance to TMZ. 
Throughout this discussion, these three themes will be discussed and future 
work proposed to progress each topic individually or to forge links between the 
themes. 
 
Manipulation of the Warburg effect to enhance the activity of anti-cancer 
drugs 
As described in chapters 1 and 2, one of the advantages cancer cells gain by 
switching to aerobic glycolysis is avoidance of apoptosis by altering 
mitochondrial membrane physiology. This not only provides cells with a 
selection advantage favouring cell survival but it also confers resistance to 
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therapeutic drugs. The hypothesis being tested in this and other studies is 
whether or not manipulation of the Warburg effect modifies mitochondrial 
function leading to reactivation of apoptosis (Michelakis et al., 2008). Inhibition 
of LDH-A and/or PDK1 have been shown to promote the activity of certain 
cytotoxic drugs by reactivating apoptosis and this is confirmed in the case for 
Etoposide (figure 2.11). Using DCA to inhibit PDK1 (figure 2.10), increased 
apoptosis was seen following the treatment of cells with Etoposide compared to 
treatment of cells with Etoposide alone (figure 2.11).  Similar results have been 
obtained for a range of cytotoxic drugs (Heshe et al., 2011; Michelakis et al., 
2010) but no studies to my knowledge have looked at the effect of inhibiting 
LDH-A and/or PDK1 on the activity of targeted therapeutics. In this study, 
combination of Bortezomib, Gefitinib, Imatinib, Masitinib, Nilotinib and Sorafenib, 
with DCA against the HCT116 p53+/+ and the combination of Bortezomib, 
Dasatinib, Gefitinib, Imatinib, Masitinib, Nilotinib, Sunitinib, and Vandetanib with 
DCA significantly potentiated the activity of DCA (figure 2.8 and table 3). It is 
possible that a similar mechanism to that proposed for cytotoxic drugs (i.e. 
reactivation of apoptosis following manipulation of the Warburg effect) is 
responsible and analysis of apoptosis induction is required as future work. It is 
also conceivable that alternative explanations exist. For example, it is not known 
what happens to the target specific signalling pathways following inhibition of 
LDH-A and/or PDK1 and further studies are required to explore these 
mechanisms. In summary, the results of this study have demonstrated for the 
first time that targeted therapeutic drugs have an effect on DVA activity and 
further studies are required to explore this further. This includes understanding 
the mechanistic basis responsible for the observed effects and investigation of 
other pharmacological variables such as scheduling (i.e. do you see the 
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enhanced effects only after inhibition of the Warburg effect) and keeping DCA 
at a constant concentration whilst varying TKI concentrations. Further studies to 
evaluate effects on other targeted therapeutics are also required in a range of 
cell types with different oncogenic drivers of the Warburg effect.     
 
Manipulating the levels of glutamine to determine how much glutamine 
needs to be depleted in order to reduce the growth or kill tumour cells 
As indicated in chapter 1 and summarised in figure 2.1, there are two major 
molecules that are catabolized in substantial quantities in cancer cells, namely 
glucose and glutamine (Wise and Thompson, 2010). Glucose and glutamine 
supply the majority of the carbon, nitrogen, free energy and reducing equivalents 
necessary to support cell growth and division in proliferating cells (Dang et al., 
2009). Research in to glutamine has provided evidence that glutamine has 
become “conditionally essential” during inflammatory conditions such as 
infection and injury (Newsholme, 2001) under healthy development. It is well 
documented that under appropriate conditions, glutamine is essential for cell 
proliferation, and that it can enhance the function of stimulated immune cells. 
On the other hand glutamine is essential for the proliferation of most cells and 
the viability of some cancer cells (Daye and Wellen, 2012). Glutamine 
metabolism contributes to the ability of cancer cells to continuously grow and 
proliferate by supporting ATP production and biosynthesis of proteins, lipids, and 
nucleic acids (DeBerardinis and Cheng, 2010) and also modulates redox 
homeostasis and can impact the activity of signal transduction pathways (Frezza 
and Gottlieb, 2009). Therefore understanding and learning about the behaviour 
of cancer cells in response to glutamine depletion remained important. The 
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experimental data obtained from the panel of cancer cell lines suggests that 
cancer cells require glutamine or are dependent on glutamine (figure 2.13). One 
strategy for targeting this property is to deplete glutamine and restrict tumour 
cell growth by eliminating this essential nutrient. The data presented in chapter 
2 demonstrates that glutamine depletion does reduce the growth of tumour cells 
in a dose dependent manner in the majority of cell lines except for A549 (figure 
2.13 and 2.14). Whilst the growth of A549 cells was reduced in glutamine-
deprived media, they still remained viable and capable of some growth. For the 
majority of cell lines tested however, glutamine deprived media had a significant 
effect on cell growth and caused cell death in many cells. In order to induce cell 
death however, glutamine levels had to be severely depleted and maintained at 
this level for a substantial time (figure 2.14). If glutamine was re-introduced to 
cells following a period of deprivation, cells were able to recover and proliferate 
(figure 2.15). These results raise two important questions with regards to 
glutamine deprivation as a strategy for treating cancer. First, can glutamine 
levels be reduced to the very low levels required to induce cell kill and second, 
can low levels of glutamine be maintained at such low levels for long enough to 
have a cytotoxic effect?  
The data presented in this thesis suggest that achieving these low levels of 
glutamine for prolonged periods of time would be challenging suggesting that 
glutamine deprivation alone is unlikely to be effective. In combination with other 
strategies targeting glutamine biochemistry (eg inhibitors of glutamine transport 
or glutamine metabolism), glutamine deprivation may enhance activity and 
further studies to explore this proposal are required. In summary, glutamine 
deprivation alone is unlikely to be effective as it is doubtful that complete 
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deprivation can be achieved in vivo and maintained for long enough to have a 
cytotoxic effect.  
 
Evaluating potential analogues of TMZ in the context of MMR/MGMT 
resistance 
TMZ is a prodrug that undergoes spontaneous decomposition to the reactive 
intermediate MTIC, which methylates the N7 and O6 positions of guanine and 
the N3 position of adenine (Tentori and Graziani, 2009) causing methylation of 
the DNA and ultimately apoptosis. However, acquired resistance to TMZ has 
developed in many cancer cells and been shown to participate in the limitation 
of therapeutic outcome. Whilst being an effective anti-cancer agent, inherent 
and acquired resistance to TMZ present major obstacles to successful treatment 
therefore necessitating the need for new and improved analogues that 
circumvent the drug resistance problem.  Identifying novel analogues of TMZ 
that retain the desirable properties of TMZ but have improved properties in terms 
of circumvention of drug resistance mechanisms was the aim.  
 
The novel analogues of TMZ were synthesised by Dr Richard Wheelhouse in 
Bradford and these were evaluated against two cell lines. A2780 is proficient in 
mismatch repair (MMR) whereas the A2780/Cis cell line is deficient in MMR. 
The other resistance mechanism for TMZ is MGMT and both A2780 and 
A2780/Cis are MGMT proficient. The MGMT inhibitor PaTrin2 was used to 
determine whether or not the activity of compounds is dependent on MGMT. 
Before setting out on the screening of compounds, the desired selection criteria 
were activity against both A2780 and A2780/Cis cells (demonstrating that the 
compounds activity was independent of MMR status) and no effect on cellular 
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response when compounds were incubated in the presence of PaTrin2 
(demonstrating that the compounds are MGMT independent). The results of this 
study demonstrated that EA02-45, 59, 64 and 65 induced cellular toxicity profiles 
that were independent of the MMR and MGMT status. The exact mechanisms 
by which these compounds evade these resistance mechanisms remains to be 
determined and further evaluation of these compounds is required. As TMZ has 
very good pharmacological properties in vivo, additional studies are required to 
evaluate the properties of the derivatives. In addition, recent studies have 
demonstrated that TMZ promotes genomic instability in patients with 
glioblastoma (Laigle-Donadey et al., 2010) leading to the emergence of a more 
aggressive disease. Additional studies are required to determine whether or not 
these new derivatives of TMZ cause similar effects or are less mutagenic than 
TMZ. In conclusion, the results of this thesis have identified novel analogues of 
TMZ that could have better properties in terms of circumvention of drug 
resistance mechanisms. This represents the start of a journey towards the 
development of second generation TMZ drugs that could have therapeutic 
value.    
 
Finally, there is scope to merge the two major themes explored in this thesis. As 
manipulation of the Warburg effect can affect key processes such as apoptosis 
leading to the enhancement of anti-cancer activity in vitro, combinations of 
inhibitors of LDH-A/PDK1 with TMZ and its derivatives would be an additional 
area for future work. Because of time constraints in this thesis, such studies 
were not conducted here but are planned for the future. What this thesis has 
demonstrated however is the potential to use the cancer cells biochemical 
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properties to enhance the activity of anti-cancer drugs and this is the major 
conclusion arising from this work. There are many challenges ahead in terms of 
translating this into in vivo studies but the results of this thesis suggest that such 
studies are warranted as the next step in the process of ultimately developing 
better therapeutic strategies for treating patients.  
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